diff --git "a/data/document_25/Health/test.csv" "b/data/document_25/Health/test.csv"
--- "a/data/document_25/Health/test.csv"
+++ "b/data/document_25/Health/test.csv"
@@ -106,5 +106,4 @@ am,en,ha,sw,yo,zu
 "የአለም ጤና ድርጅት ስትራቴጂካዊ አቅጣጫዎችን እና ተነሳሽነቶችን ለመምራት ቁልፍ የአመራር ሹመቶች የዓለም ጤና ድርጅት (WHO) በጄኔቫ በሚገኘው ዋና መሥሪያ ቤቱ አመራር ቡድን ውስጥ አምስት አዳዲስ ከፍተኛ ሰዎችን ሾሟል። አዲሶቹ ሹመቶች ዶ/ር ቴዎድሮስ አድሃኖም ገብረእየሱስን ለሁለተኛ አምስት ዓመታት በዋና ዳይሬክተርነት መሾማቸውን ተከትሎ ነው። አጠቃላይ የአመራር ቡድኑ ለቀጣዮቹ አምስት አመታት ከድርጅቱ ቅድሚያ ከሚሰጣቸው ጉዳዮች ጋር እንዲጣጣም የተጠናከረ ሲሆን እነዚህን ቅድሚያ የሚሰጣቸውን ጉዳዮች እና የአለም ጤና ድርጅትን ትልቅ የለውጥ አጀንዳ ለማስቀጠል ከዋና ዳይሬክተር ጋር በቅርበት ይሰራሉ። የአለም ጤና ድርጅት 13ኛ አጠቃላይ የስራ መርሃ ግብር (GPW13) አተገባበር እና የ""ሶስትዮሽ ቢሊየን"" ግቦችን እና ከጤና ጋር የተያያዙ የዘላቂ ልማት ግቦችን ለማሳካት እድገትን ለማፋጠን ለሚቀጥሉት አምስት አመታት የአለም ጤና ድርጅት ስራ በአምስት ቅድሚያዎች ላይ ያተኮረ ነው። ጤናን ወደ ማጎልበት እና የበሽታን መንስዔዎችን በመቅረፍ ማዕቀፍ ለውጥ ማድረግ; የጤና ስርዓቶችን ወደ የመጀመሪያ ደረጃ ጤና አጠባበቅ ማስተካከል; ለጤና ድንገተኛ አደጋ ዝግጁነት እና ምላሽ ስርዓቶችን ማጠናከር; የጤና ጥበቃን ወደፊት ለማራመድ የሳይንስ፣ ፈጠራ፣ መረጃ እና ቴክኖሎጂዎች ኃይልን መጠቀም; እና የዓለም ጤና ድርጅትን እንደ መሪ ባለስልጣን ማጠናከር እና በአገሮች ላይ ተጽእኖ ማሳደር። እኩል ቁጥር ያላቸውን የሴቶች እና የወንዶች ቁጥር ያቀፈው የዋናው መሥሪያ ቤት አመራር ቡድን ከዓለም ጤና ድርጅት የክልል እና የሀገር ውስጥ ቢሮዎች ጋር በጋራ ይሰራል። የዋናው መሥሪያ ቤት አመራር ቡድን አዲስ አባላት፡ ዶ/ር ጄረሚ ፋራራ እ.ኤ.አ ከግንቦት 8 ቀን 2023 ጀምሮ የዓለም ጤና ድርጅት ዋና ተመራማሪ ይሆናሉ። የዶ/ር ፋራር ሹመት ቀደም ብሎ እ.ኤ.አ በታኅሣሥ 2022 ይፋ ነበር። በዚህ ተግባር ዶ/ር ፋራር የሳይንስ ክፍልን ይቆጣጠራሉ፣ በዓለም ዙሪያ ያሉ ምርጥ የሳይንስ እና ፈጠራ ባለሙያዎችን እና ኔትወርኮችን በማሰባሰብ ከፍተኛ ጥራት ያላቸውን የጤና ፖሊሲዎች እና አገልግሎቶችን በጣም ለሚያስፈልጋቸው ሰዎች እንዲመሩ፣ እንዲያዘጋጁ እና እንዲያቀርቡ ያደርጋል። ወደ አለም ጤና ድርጀት (WHO) ከመቀላቀላቸው በፊት ዶ/ር ፋራር የዌልኮም ትረስት ዳይሬክተር ነበሩ። እ.ኤ.አ በ2013 ዌልኮምን ከመቀላቀሉ በፊት ዶ/ር ፋራር በቬትናም በሚገኘው የሀሩር ክልል በሽታዎች ሆስፒታል የክሊኒካል ምርምር ክፍል ዳይሬክተር በመሆን 17 ዓመታትን አሳልፈዋል፣ የምርምር ፍላጎቶቹ በሚከሰቱ ተላላፊ በሽታዎች ላይ በማተኮር በዓለም አቀፍ ጤና ላይም ያተኮሩ ነበሩ። ዶ/ር ፋራራ የህክምና ዲግሪ እና ፒኤችዲ ያለው ክሊኒካዊ ተመራማሪ ነው። ዶ/ር አይላን ሊ እ.ኤ.አ ከግንቦት 8 ቀን 2023 ጀምሮ ሁለንተናዊ የጤና ሽፋን፣ ጤናማ ህዝቦች ረዳት ዋና ዳይሬክተር ይሆናሉ። በዚህ ሚና ዶ / ር ሊ የአየር ንብረት ለውጥን ፣ የትምባሆ ቁጥጥርን ፣ የኬሚካል ደህንነትን ፣ የመንገድ ደህንነትን ፣ የምግብ ስርዓቶችን ጨምሮ ከአካባቢ ፣ ከማህበራዊ እና ኢኮኖሚያዊ የጤና ጉዳዮች ጋር በተያያዙ ጣልቃገብነቶች የተሻለ ጤና እና ደህንነትን ለማስተዋወቅ እና የተመጣጠነ ምግብ፣ የአካል ብቃት እንቅስቃሴ፣ የአየር ብክለት እና ጨረሮች በአንድ ጤና አቀራረብ የሚያረገውን የድርጅቱን ጥረት ይቆጣጠራል። ዶ/ር ሊ እ.ኤ.አ ከሀምሌ 15 ቀን 2019 ጀምሮ በካምቦዲያ መንግሥት የዓለም ጤና ድርጅት ተወካይ ሆነው እያገለገሉ ነው። ከዚህ ሚና በፊት ዶ / ር ሊ በምዕራብ ፓስፊክ ውስጥ በአለም ጤና ድርጅት ክልላዊ ቢሮ ውስጥ ለ አለም ጤና ድርጅት የጤና ድንገተኛ አደጋዎች መርሃ ግብር የክልል ድንገተኛ አደጋ ዳይሬክተር ሆነው አገልግለዋል። ዶ/ር ሊ በጤና ማህበራዊ ሳይንስ ዲግሪ እና የህክምና ዲግሪ አላቸው። ዶ/ር ዩኪኮ ናካታኒ እ.ኤ.አ ከግንቦት 2 ቀን 2023 ጀምሮ የመድኃኒት እና የጤና ምርቶች ተደራሽነት ረዳት ዋና ዳይሬክተር ይሆናሉ። በዚህ ሚና ዶ/ር ናካታኒ የ አለም ጤና ድርጅት ደንቦች እና ፖሊሲዎች ልማት እና አተገባበር ይቆጣጠራሉ ፣ ይህም ወረርሽኞችን ለመከላከል እና ምላሽ ለመስጠትን ጨምሮ በሁሉም ቦታ ለሚገኙ ሁሉም ህዝቦች ጥራት ያለው መድሃኒት ፣ ክትባቶች እና ምርመራዎች ፍትሃዊ ተደራሽነትን ለማረጋገጥ ነው። ዶ/ር ናካታኒ የጃፓን የጤና፣ የሰራተኛ እና ደህንነት ጥበቃ ሚኒስቴር የካንሰር እና የበሽታ መቆጣጠሪያ ክፍል ዳይሬክተር እና በጃፓን ለኮቪድ-19 የክትባት ግብረ ኃይል ሚኒስትር ዴኤታ የቴክኒክ አማካሪ ሆነው ሲያገለግሉ ቆይተዋል።","Key leadership appointments made to drive WHO strategic direction and initiatives The World Health Organization (WHO) has appointed five new senior figures to its headquarters leadership team in Geneva. The new appointments follow the reappointment of Dr Tedros Adhanom Ghebreyesus to his second five-year term as Director-General. The overall leadership team has been consolidated to align with the Organization’s priorities for the next five years and will work closely with the Director-General to drive forward these priorities and WHO’s ambitious transformation agenda. To accelerate progress on implementation of WHO’s 13th General Programme of Work (GPW13), and achievement of its “triple billion” targets and the health-related Sustainable Development Goals, WHO’s work for the coming five years is focused on five priorities: making a paradigm shift towards promoting health and preventing disease by addressing its root causes; radically reorienting health systems towards primary health care; strengthening the systems for health emergency preparedness and response; harnessing the power of science, innovation, data and technologies to advance health; and strengthening WHO as the leading authority on global health and to achieve impact in countries. The headquarters leadership team, comprising equal numbers of women and men, will work jointly with WHO regional and country offices. New members of the headquarters leadership team: Dr Jeremy Farrar will become WHO’s Chief Scientist as of 8 May 2023. The appointment of Dr Farrar was previously announced in December 2022. In this role Dr Farrar will oversee the Science Division, bringing together the best experts and networks in science and innovation from around the world to guide, develop and deliver high quality health policies and services to the people who need them most. Prior to joining WHO Dr Farrar was Director of the Wellcome Trust. Before joining Wellcome in 2013 Dr Farrar spent 17 years as Director of the Clinical Research Unit at the Hospital for Tropical Diseases in Vietnam where his research interests were in global health with a focus on emerging infectious diseases. Dr Farrar is a clinician researcher with a medical degree and a PhD. Dr Ailan Li will become Assistant Director-General for Universal Health Coverage, Healthier Populations as of 8 May 2023. In this role Dr Li will oversee the Organization’s efforts to promote better health and well-being through interventions relating to the environmental, social, and economic determinants of health, including climate change, tobacco control, chemical safety, road safety, food systems and nutrition, physical activity, air pollution and radiation, through a One Health approach. Dr Li has been serving as the WHO Representative to the Kingdom of Cambodia since 15 July 2019. Prior to this role, Dr Li served as Regional Emergency Director for the WHO Health Emergencies Programme in the WHO Regional Office for the Western Pacific. Dr Li holds a medical degree and degree in health social sciences. Dr Yukiko Nakatani will become Assistant Director-General for Access to Medicines and Health Products as of 2 May 2023. In this role Dr Nakatani will oversee the development and implementation of WHO’s norms and policies to ensure equitable access to quality medicines, vaccines and diagnostics for all populations everywhere, including for preventing and responding to epidemics. Dr Nakatani has been serving as the Director of the Cancer and Disease Control Division of the Japanese Ministry of Health, Labour and Welfare and as the Technical Advisor to the Minister of State for the COVID-19 Vaccination Task Force in Japan.","an naɗa muƙamai 143 domin jan ragamar ayyukan Hukumar Lafiya ta Duniya. Hukumar Lafiya ta Duniya (WHO) ta naɗa sabbin manyan jami'an biyar zuwa shalkwatarta da ke Geneva. Sabbin naɗe-naɗen sun biyo bayan sake naɗa Dakta Tedros Adhanom Ghebreyesus a matsayin darakta-janar, inda zai yi shekaru 5 ƙari kan wa'adinsa na farko. An buƙaci ɗaukacin shuwagabannin da aka naɗa da su sanya muradun hukumar a gaba a cikin shekaru biyar da za su yi masu zuwa da kuma yin aiki tare da darakta-janar wajen cimma waɗannan muradu da burin Hukumar Lafiya ta Duniya na kawo sauye-sauye. Domin tabbatar da cimma aiwatar da Tsararrun Manufofin Ayyukanta Karo na 13(GPW13) da ta ware wa biliyoyin kuɗi da cimma Muradun Raya Ƙasa Mai Ɗorewa da suka shafi lafiya, Hukumar Lafiya ta Duniya za ta kula da wasu muhimman abubuwan guda biyar: Sauya dabarun fuskantar abin da ya shafi haɓaka lafiya da kare afkuwar cututtuka ta hanyar magance musabbabansu daga tushe. sauya tsarin lafiya zuwa ba wa cibiyoyin lafiya matakin farko muhimmanci; Ƙarfafa tsarin zama ciki shirin ko-ta-kwana domin kai agajin gaggawa a fannin lafiya. Amfani da tasirin kimiyya da ƙere-ƙere da rahotanni da fasahohi wajen ciyar da lafiya gaba, da ƙarfafa tasirin Hukumar Lafiya ta Duniya (WHO) a matsayin jagoran kan duk abin da ya shafi lafiya a duniya domin cimma muradunta a ƙasashe. shugabannin shalkwatar da suka haɗa adadi kai ɗaya tsakanin maza da mata, za su yi aiki tare sauran ofisoshin hukumar da ke yankuna da ƙasashe. Cikin sabbin jagororin da ke shalkwatar, Dakta Jeremy Farrar ne zai zama babban jami'in kimiyya na Hukumar Lafiya ta Duniya daga 8 ga watan Mayun 2023. A baya an sanar da naɗin Dakta Farrar a cikin Disamba 2022. A cikin wannan aikin, Dakta Farrar zai kula da dukkanin sashen Kimiyya tare da tattaro kan ƙwararrun masana da hanyoyin sadarwa na kimiyya da ƙere-ƙere daga ko ina a faɗin duniya ya jagoranta, ya tabbatar da ci gaba da isar da ingantattun manufofi da ayyuka na kiwon lafiya ga mutanen da suke buƙatar su. Kafin Dakta Farrar ya fara aikin Hukumar Lafiya ta Duniya wato WHO, ya kasance Darakta ne a Wellcome Trust. Kafin shigarsa Wellcome a shekarar 2013, Dakta Farrar ya shafe shekaru 17 a matsayin Daraktan Sashin Bincike gwaje-gwaje a Asibitin cututtuka masu saurin yaɗuwa ta ƙasar Vietnam inda yafi mayar da hankalin bincikensa kan kiwon lafiyar duniya tare da bincike kan sabbin cututtukan da ke tasowa. Dakta Farrar mai bincike ne wanda ke da digiri na farko har zuwa na uku wato PhD a fannin likitanci. Dakta Ailan Li zai zama Mataimakin Darakta-Janar na hukumar Universal Health Coverage Healthier Populations tun daga ranar 8 ga Mayu 2023. A cikin wannan mataki, Dakta Li zai kula da ƙoƙarin ƙungiyar don tabbatar da ingantacciyar lafiya da walwala ta hanyar tsoma baki akan al'amuran da suka shafi muhalli, zamantakewa, da tattalin arziki na kiwon lafiya, gami da sauyin yanayi, sarrafa sigari, amincin sinadarai, kula da hanyoyi, abinci, tsarin abinci mai gina jiki, motsa jiki, gurɓatacciyar iska da radiation, ta hanyar One Health. Dr Li yana aiki a matsayin wakilin Hukumar WHO a Masarautar Cambodia tun daga ranar 15 ga Yuli 2019. Kafin wannan rawar, Dakta Li ya kasance Daraktan Gaggawa na Shirin Agajin Lafiya na Hukumar WHO a Ofishin Yanki na WHO na Yammacin Pacific. Dakta Li yana da digiri na likitanci da digiri a fannin kimiyyar zamantakewar lafiya. Dakta Yukiko Nakatani zai zama Mataimakin Darakta-Janar na Samumar da Magunguna da Kayayyakin Lafiya tun daga ranar 2 ga watan Mayu 2023. A wannan muƙamin, Dakta Nakatani zai sa ido kan ci gaba da aiwatar da ƙa'idoji da manufofin Hukumar WHO don tabbatar da samun daidaiton damar samun ingantattun magunguna, alluran rigakafi da binciken lafiya ga dukkan al'ummomi a ko'ina, gami da rigakafi annoba. Dakta Nakatani ya kasance Daraktan Sashin Kula da Cututtukan Daji na Ma'aikatar Lafiya, Ƙwadago da Jin Daɗin Jama'a ta Ƙasar Japan kuma a matsayin mai ba da shawara na fasaha ga Karamin Ministan Kula da Rigakafin Cutar COVID-19 a Ƙasar Japan.","Uteuzi muhimu wa uongozi ulifanywa ili kusimamia muelekeo na mipango ya kimkakati ya WHO Shirika la afya Duniani (WHO) limeteua vigogo watano wapya kwa tume yake ya uongozi ya makao makuu mjini Jeniva. Uteuzi huo mpya unafuatia kuteuliwa tena kwa Dk Tedros Adhanom Ghereyesus katika muhula wake wa pili wa miaka mitano kama mkurugenzi mkuu. Timu ya jumla ya uongozi imeunganishwa ili kuendana na vipaumbele vya shirika kwa miaka mitano ijayo na itafanya kazi kwa karibu na mkurugenzi mkuu ili kuendeleza vipaumbele hivi na ajenda ya mabadiliko ya WHO. Ili kuharakisha maendeleo katika utekelezaji wa mpango mkuu wa 13 wa kazi za WHO (GPW13), kufikia malengo yake ya ""Bilioni tatu"" na malengo ya maendeleo endelevu yanayousiana na afya, kazi ya WHO kwa miaka mitano ijayo inazingatia vipaumbele vitano: Kufanya mabadiliko ya mtazamo kuelekea kukuza afya na kuzuia magonjwa kwa kushughulikia vyanzo vyake; Kuelekeza upya mifumo ya afya kuelekea huduma ya afya ya msingi Kuimarisha mifumo ya maandalizi na majibu ya dharura ya afya; Kutumia nguvu ya sayansi, uvumbuzi , Data na teknolojia ili kuendeleza afya; na Kuimarisha WHO kama mamlaka inayoongoza kwa afya Duniani na kufikia athari katika nchi. Timu ya uongozi ya makao makuu, inayojumuisha idadi sawa ya wanawake na wanaume, itafanya kazi kwa pamoja na ofisi za WHO za kikanda na nchi. Wanachama wapya wa timu ya uongozi ya makao makuu: Dk Jeremy Farrar atakuwa mwanasayansi mkuu wa WHO kuanzia tarehe 8 Mei 2023. Uteuzi wa Dk Farrar ulitangazwa hapo awali mwezi Desemba 2022. Katika jukumu hili Dk Farrar atasimamia kitengo cha sayansi, akiwaleta pamoja watalaamu wobobezi na mitandao katika sayansi na uvumbuzi kutoka Duniani kote ili kuongoza, kuendeleza na kutoa sera na huduma za afya za ubora wa juu kwa watu wanaohitaji zaidi. Kabla ya kujiunga na WHO Dk Farrar alikuwa mkurugenzi wa Wellcome Trust. Kabla ya kujiunga na Wellcome mwaka 2013 Dk Farrar alitumia miaka 17 kama mkurugenzi wa kitengo cha utafiti wa Kliniki katika hospitali ya magonjwa ya kitropiki nchini Vietnamu ambapo maslahi yake ya utafiti yalikuwa katika afya ya kiamataifa kwa kuzingatia magonjwa ya kuambukiza yanajitokeza. Dk Farrar ni mtafiti wa kliniki mwenye shahada ya matibabu na shahada ya Uzamivu. Dkt Alian Li atakuwa mkurugenzi mkuu msaidizi wa huduma ya afya kwa wote, idadi ya watu wenye afya bora kuanzia tarehe 8 Mei 2023. Katika jukumu hili Dk Li atasimamia juhudu za shirika za kukuza afya bora na ustawi kupitia afua zinazohusu viashiria vya afya kimazingira, kijamii na kiuchumi, ikijumuisha maadiliko ya Tabianchi, udhibiti wa Tumbaku, usalama wa kemikali, usalama wa barabarani, mifumo ya chakula na lishe, shughuli za kawaida, uchafuzi wa hewa na mionzi, kupitia mbinuya Afya ya Pamoja. Dk Li amekuwa akihudumu kama mwakilishi wa WHO katika Ulaflme wa Kambodia tangu 15 julai 2019. Kabla ya jukumu hili, Dk Li aliwahi kuwa mkurugenzi wa Dharura wa kanda wa mpango wa dhrura wa afya wa WHO katika ofisi ya kanda ya WHO ya Pasifiki Magharibi. Dk Li ana shahada ya matibabu na shahada katika Sayansi ya afya ya kijamii. Dkt Yukiko Nakatani atakuwa mkurugenzi mkuu msaidizi wa upatikanaji wa dawa na bidhaa za afya kuanzia tarehe 2 Mei 2023. Katika jukumu hili Dk Nakatani atasimamaia maendeleo na utekelezaji wa kanuni na sera za WHO ili kuhakikisha upatikanaji sawa wa dawa bora, chanjo na uchunguzi kwa watu wote kila mahali, ikiwa ni pamoja na kuzuia na kukabiliana na magonjwa ya mlipuko. Dkt Nakatani amekuwa mkurugenzi wa kitengo cha kudhibiti saratani na magonjwa cha wizara ya afya, kazi na ustawi wa Japani na kama mshauri wa kiufundi wa waziri wa nchi wa kikosi kazi cha chanjo ya UVIKO-19 nchini Japani.","Àwọn ìyàn sípò aṣíwájú pàtàkì tí wọ́n ṣe láti darí ìlànà-iṣẹ́ ìdarí àti ìpilẹ̀ṣẹ̀ WHO Àjọ Elétò Ìlera Àgbáyé (WHO) ti ṣe ìyànsípò àwọn lọ́gà-lọ́gà márùn-ún tuntun sí ikò adarí olú ilé-iṣẹ́ rẹ̀ ní Geneva. Àwọn ìyànsípò tuntun náà tẹ̀lé ìtúnni yàn sípò Dr Tedros Adhanom Ghebreyesus sí sáà ọlọ́dún-márùn-ún kejì gẹ́gẹ́ bíi Olùdarí-Àpapọ̀. Àpapọ ikọ̀ àwọn olùdarí náà ni wọ́n ti ṣe láti dọ́gba pẹ̀lú àwọn ohun pàtàkì Àjọ náà fún ọdún márùn-ún tó ń bọ̀ tí wọn ó sì ṣiṣẹ́ papọ̀ pẹ̀lú Olùdarí-Àpapọ̀ láti mú ìtẹ̀síwájú bá àwọn nǹkan pàtàkì wọ̀nyìí àti èròngbà àyípadà àlá WHO. Láti mú kí ìlọsíwájú yá lórí ìṣàmúlò Ètò Àpapọ̀ fún Iṣẹ́ WHO 13th (GPW13), àti àṣeyọrí àfojúsùn ""bílíọ̀nù mẹ́ta"" rẹ̀ àti Àwọn Èròngbà Ìdàgbàsókè Alálòpẹ́ ajẹmọ́-ìlera náà, iṣẹ́ WHO fún ọdún márùn-ún tó ń bọ̀ dá lórí àwọn nǹkan pàtàkì márùn-ún: ṣíṣe àyípadà iṣẹ́ lọ sí ibi ìpolongo ìlera àti ìdènà ààrùn pẹ̀lú kíkojú àwọn aṣokùnfà ìpìlẹ̀ rẹ̀; ṣíṣe àtúntò àwọn ètò ìlera fún ètò ìlera alábọ́dé láti ìpìlẹ̀; Ríró àwọn ètò náà lágbára fún ìmúrasílẹ̀ àti ìdáhùn sí pàjáwírì ìlera; ṣíṣe àmúlò agbára sáyẹ́nsì, ìmọ̀ ọ̀tun, dátà àti àwọn ìmọ̀ ẹ̀rọ láti mú ìlọsíwájú bá ilera; àti ríró WHO lágbára gẹ́gẹ́ bíi aláṣẹ tó ń léwájú lórí ìlera àgbáyé àti láti ṣe àṣeyọrí ipa ní àwọn orílẹ̀-èdè. Ikọ̀ adarí olú ilé-iṣẹ́ náà, tó jẹ́ àpapọ iye àwọn ọkùnrin àti àwọn obìnrin kan náà, máa ṣiṣẹ́ papọ̀ pẹ̀lú àwọn ọ́fíísì ẹkùn agbègbè àti orílẹ̀-èdè. Àwọn ọmọ ẹgbẹ́ tuntun nínú ikọ̀ adarí olú ilé-iṣẹ́ náà náà: Dr Jeremy Farrar máa di Olórí Onímọ̀ Sáyẹ́nsì WHO láti 8 oṣù Èbìbí ọdún 2023. Ìyànsípò Dr Farrar ni wọ́n ti kọ́kọ́ kéde ní oṣù Ọ̀pẹ ọdún 2022. Nínú ipò yìí Dr Farrar máa ṣàmójútó Ẹ̀ka Ìmọ Sáyẹ́nsì, tí yóò ṣe àkójọpọ̀ àwọn akọ́ṣẹ́mọṣẹ́ àti àwọn ojú òpó tó dára jùlọ àti nínú ìmọ sáyẹ́nsì àti ìmọ̀ ọ̀tun jákèjádò àgbáyé láti ṣe ìtọ́nisọ́nà, àgbédìde àti àgbékalẹ̀ àwọn ojúlówó òfin ìlera àti ìpèsè iṣẹ́ fún àwọn ènìyàn tí wọ́n nílò rẹ̀ jùlọ. Ṣíwájú kí ó tó darapọ̀ mọ́ WHO Dr Farrar ni Olùdarí fún Wellcome Trust. Kí ó tó darapọ̀ mọ́ Wellcome ní ọdún 2013 Dr Farrar lo ọdún 17 gẹ́gẹ́ bíi Olùdarí fún Ẹ̀ka Ìwádìí Ajẹmọ́-ìlera ní Ilé Ìwòsàn fún Àwọn Ààrùn Ìgbóná ní Vietnam níbi tí àwọn àfojúsùn ìwádìí ti dá lórí ìlera àgbáyé pẹ̀lú àdojúkọ àwọn ààrùn àkóràn tó ń jẹyọ. Dr Farrar jẹ́ oníwádìí ajẹmọ́-ìlera pẹ̀lú ìwé ẹ̀rí ìṣègùn àti PhD. Dr Ailan Li máa di Igbákejì Olùdarí-Àpapọ̀ fún Kíkárí Ìlera Àgbáyé, Àwọn Ènìyàn Tó Ní Àlàáfíà láti 8 oṣù Èbìbí ọdún 2023. Nínú ipò yìí Dr Li máa ṣàmójútó àwọn ìgbìyànjú Àjò náà láti ṣe àtìlẹ́yìn fún ìlera tó dára àti ìgbáyégbádùn nípasẹ̀ àwọn ìdásí tó níṣe pẹ̀lú agbègbè, àwùjọ, àti àwọn aṣokùnfà ọrọ̀ ajé fún ìlera, tó fi mọ́ àyípadà ojú ọjọ́, ìdarí tábà, ààbò kẹ́míkà, ààbò ojú pópó, àwọn ètò oúnjẹ àti èròjà aṣara lóore, àwọn iṣẹ́ àfojúrí, bíba afẹ́fẹ́ jẹ́ àti ìtànkálẹ̀, nípasẹ ìlànà Ìlera Kan. Dr Li ti ń ṣiṣẹ́ gẹ́gẹ́ bíi Aṣojú WHO ní Kingdom of Cambodia láti 15 oṣù Agẹmọ ọdún 2019. Ṣíwájú ipò yìí, Dr Li ti ṣiṣẹ́ gẹ́gẹ́ bíi Olùdarí Pàjáwírì Ẹkùn Agbègbè fún Ètò Àwọn Pàjáwírì Ìlera WHO ní Ọ́fíísì Ẹkùn Agbègbè WHO fún Western Pacific. Dr Li ní ìwé-ẹ̀rí ìṣẹ̀gun àti ìwé-ẹ̀rí nínú sáyẹ́nsì ìlera àwùjọ. Dr Yukiko Nakatani máa di Igbákejì Olùdarí-Àpapọ̀ fún Ànfààní sí Àwọn Oògùn àti Àwọn Ohun Èlò Ìlera láti 2 oṣù Èbìbí ọdún 2023. Nínú ipò yìí Dr Nakatani máa ṣàmójútó àgbékalẹ̀ àti àmúlò àwọn ìṣe àti òfin WHO láti ṣe àrídájú ànfààní sí adọ́gba sí àwọn ojúlówó oògùn, àwọn àjẹsára àti àyẹ̀wò fún ààrùn fún gbogbo àwọn ènìyàn ní ibi gbogbo, tó fi mọ́ ìdènà àti ìdáhùn sí àjàkálẹ̀ ààrùn. Dr Nakatani ti ń ṣiṣẹ́ gẹ́gẹ́ bíi Olùdarí fún Ẹ̀ka Ààrùn Jẹjẹrẹ àti Ìdènà Ààrùn ti Ilé-iṣẹ́ Ìjọba tó ń Rí Sí Ètò Ìlera, Òṣìṣẹ́ àti Ìgbáyégbádùn ní orílẹ̀-èdè Japan àti gẹ́gẹ́ bíi Olùbánidámọ́ràn ìmọ̀ ẹ̀rọ fún Mínísítà fún Ìpínlè fún Àwọn Òṣìṣẹ́ Abẹ́rẹ́ Àjẹsára COVID-19 ní orílẹ̀-èdè Japan.","Ukuqokwa kobuholi oubalulekile okwenziwelwe ukuhambisa indlela yesu nemizamo yeWHO Inhlangano yeZempilo yoMhlaba (WHO) sebeqoke izikhulu eziphezulu iminyaka emihlanu ukuba ngabaholi eqembini labaholi ekomkhulu eGeneva. Ukuqokwa okusha kulandela ukuphinde kuqokwe uDkt Tedros Adhanom Ghebreyesus kuhlandla lesibili leminyaka emihlanu njengoMqondisi Jikelele. Ubuholi bonkebeqembu buhlanganiswe ukuhambisana nokuhamba phambili kweNhlangano kuleminyaka emihlanu ezayo nokusebenzisana noMqondisi Jikelele ukuhambisa okuya kukhona okuhamba phambili ne-ajenda yentshisekelo yoguquko lweWHO. Ukuqhuba inqubekela phambili yokwenza kweWHO 13th General Programme of WORK (GPW13) ukuthola okuqondiwe ""okungezigidigidi ezintathu"" nokuhlobene nezempilo zeSuatainable Development Goals, umsebenzi weWHO kuleminyaka emihlanu ezayo egxile kokuhamba phambili okuhlanu: ukwenza ukulandelana ngendlela okuya ekugqugquzeleni ezempilo nokuvikela isifo ngokubhekana nomsuka ozidalayo; ushintsho olwenzekayo kuzinhlelo zezempilo okuya ekunakekelweni kwezempilo zokuqala; ukuqinisa izinhlelo zokuzilungiselela okuphuthumayo nokuphendula; amahhanisi amandla esayensi,ukwenza kabusha,idatha nezobuchwepheshe ukwenzangcono ezempilo; kanye nokuqinisa iWHO njengabanegunya lokuhola kwezempilo zomhlaba nokuthola umthelela emazweni. Qembu labaholi ekomkhulu, linenamba elinganayo kubantu besifazane nabesilisa, bazosebenza ngokuhlanganyela nesifunda seWHO namahhovisi emazweni. Amalungu amasha eqembu lobuholi ekomkhulu:uDkt Jeremy Farrar ozoba nguSosayensi omkhulu weWHO kusukela ngomhlaka-8 kuNhlaba 2023. Ukuqokwa kukaDkt Farrar kwamenyezelwa ngoZibandlela 2022. Kulesisikhundla uDkt Farrar uzobheka umkhakha wezesayensi, ukuhlanganisa ndawonye ngoti abaphambili nohlelokuxhumana kwezesayensi nokwenza kabusha emhlabeni wonke ukuyalela, ukudevelopha nokuhambisa ezempilo ezisezingeni eliphezulu inqubomgomo nemisebenzi kubantu abayidinga kakhulu. Ngaphambi kokujoyina iWHO uDkt Farrar ubenguMqondisi weWellcome Trust. Ngaphambi kokujoyina Wellcome ngo-2013 uDkt Farrar uchithe iminyaka engu-17 njengoMqondisi weClinical Reaserch Unit esiBhadlela seTropical Diseases eVietnam lapho ukucwaninga kwakhe kwakugxile kwezempilo emhlabeni ngokugxila ekuveleni kwezifo ezithelelanayo. UDkt Farrar ungumcwaningi wezokwelapha neziqu zobudokotela kanye nePHD. UDkt Ailan Li uzoba nguMsizi Mqondisi Jikelele weUniversal Health Coverage,Healthier Populations kusukela ngomhlaka-8 kuNhlaba 2023. Kulesisikhundla uDkt Li izobheka imizamo yeNhlangano ukugqugquzela ukubangcono kwezempilo nokuphila ngokungenelela okuhlobene nezendawo ezenhlalakahle, ezempilo zokubhekene nezomnotho okufaka ukuguquka kwesimo sezulu, ukulawula ugwayi, ukuphepha kwamakhemikhali, ukuphepha komgwaqo, izinhlelo zokudla nokunomsoco, ukusebenza siqu, ukungcoliswa komoya nokwemisebe yelana ngendlela ye-One Health. UDkt Li ubelokhu esebenza njengomele iWHO eKingdom of Cambodia kusukela ngomhlaka-15 kuNtulikazi 2019. Ngaphambi kwalesisikhundla, uDkt Li wasebenza njenge Regional Emergency Director weWHO Health Emergencies Programme eHhovisi leSifunda leWHO eWestern Pacific. UDkt Li uneziqu zobudokotela neziqu kwezesayensi yenhlalakahle yezempilo. UDkt Yukiko Nakatani uzoba nguMszi woMqondisi Jikelele wokungena kwezemithi nokukhiqizwa nemikhiqizo yezempilo. Kulesisikhundla uDkt Nakatani uzobheka ukuthuthuka nokwenza kwemigomo yeWHO nezinqubomgomo ukuqinisekisa ukutola ukulingana kumithi efanele, imigomo kanye nokuxilongwa kusona sonke isibalo sabantu yonke indawo okufaka ukuvikela nokuphendula ku-ephidemikhi. UDKt Nakatani ususebenze njengoMqondisi woMdlavuza nedivishini yokulawula izifo eJapanese uNgqongqoshe weZmpilo,ezokusebenza nenhlalakahle njengoTechnica Advisory kuMinister of State wezokusebenza zokugoma iCOVID-19 eJapan."
 ዶ/ር ናካታኒ የሕክምና ዲግሪ እና በሕዝብ ጤና ፒኤችዲ አግኝተዋል። ዶ/ር ራዝያ ፔንድሴ እ.ኤ.አ ከግንቦት 4 ቀን 2023 ጀምሮ የሼፍ ዲ ካቢኔ ሆና ተሹማለች። በዚህ ተግባር ዶ/ር ፔንድሴ የድርጅቱን ቅድሚያ የሚሰጣቸውን ተግባራት እና ተነሳሽነቶችን በማገዝ የጄኔራል ዳይሬክተሩን ጽህፈት ቤት ይመራሉ እና በአለም ጤና ድርጅት አመራር ቡድን እና በአለም ጤና ድርጅት ሶስት እርከኖች መካከል ያለውን አሰላለፍ ታረጋግጣለች። ዶ/ር ፔንድሴ በጤናማ ህዝብ እና ተላላፊ ያልሆኑ በሽታዎች ዳይሬክተር ሆነው በአለም ጤና ድርጅት ክልላዊ ቢሮ ለደቡብ-ምስራቅ እስያ ሲያገለግሉ የቆዩ ሲሆን ቀደም ሲል የዓለም ጤና ድርጅት በስሪላንካ ተወካይ ነበሩ። ዶ/ር ፔንደሴ በሕዝብ ጤና ሁለተኛ ዲግሪ እና የሕክምና ዲግሪ አላቸው። ዶ/ር ጄሮም ሰሎሞን እ.ኤ.አ ከመጋቢት 17 ቀን 2023 ጀምሮ ለአለም አቀፍ የጤና ሽፋን፣ ተላላፊ እና ተላላፊ ያልሆኑ በሽታዎች ረዳት ዋና ዳይሬክተር ሆነው ተሹመዋል። በዚህ ተግባር ዶ/ር ሰሎሞን ኤችአይቪ፣ ሄፓታይተስ መባዛትን፣ በግብረ ሥጋ ግንኙነት የሚተላለፉ ኢንፌክሽኖች፣ ሳንባ ነቀርሳ፣ ወባ፣ ችላ የተባሉ የሞቃታማ ክልል በሽታዎች፣ የአዕምሮ ጤና፣ሥር የሰደደ የመተንፈሻ አካላት በሽታዎች እና ካንሰርን፣ የአደንዛዥ እጾች መዛባት እና ተላላፊ ያልሆኑ በሽታዎችን እንደ የልብና የደም ቧንቧ በሽታ፣ የስኳር በሽታ የመሳሰሉ ሰፋ ያሉ የቴክኒክ ፕሮግራሞችን ይቆጣጠራሉ። ዶ/ር ሰሎሞን በፈረንሳይ ጤና ጥበቃ ሚኒስቴር የጤና ጥበቃ ዋና ዳይሬክተር ሆነው ሲያገለግሉ ቆይተዋል። ከመሾሙ በፊት የአለም ጤና ድርጅት ስራ አስፈፃሚ ቦርድ አባል የነበሩ እና በጤና ስርአት አያያዝ፣ ተላላፊ በሽታዎች እና አለም አቀፍ የህብረተሰብ ጤና ላይ ሰፊ ልምድ ያላቸው ናቸው። ዶ/ር ሰሎሞን የሕክምና ዲግሪ፣ በሕዝብ ጤና ማስተርስ ዲግሪ እና በኤፒዲሚዮሎጂ ፒኤችዲ አግኝተዋል። የዋና መሥሪያ ቤቱ አመራር ቡድን ነባር አባላት የስልጣንና የልምድ ደረጃ፡- ዶ/ር ሰሚራ አስማ የመረጃ፣ ትንታኔ እና ለተፅእኖ አቅርቦት ረዳት ዋና ዳይሬክተር ሆነው ይቀጥላሉ። የዶ/ር አስማ የስራ ሀላፊነት ከተባለው በላይ ሲሰፋ፣ የጤና መረጃዎች አስተማማኝ እና ተደራሽ መሆናቸውን በማረጋግጥ እና በዓለም ዙሪያ የጤና ውጤቶችን ለማሻሻል ጥቅም ላይ የሚውሉ የሶስት ቢሊዮን ግቦችን መከታተል እና ማፋጠን እና ከጤና ጋር የተገናኙ የዘላቂ ልማት ግቦች ይቆጣጠራሉ። ዶ/ር አስማ እ.ኤ.አ በ2018 የአለም ጤና ድርጅትን ከመቀላቀላቸው በፊት በዩኤስ የበሽታ መቆጣጠሪያ እና መከላከያ ማእከል (CDC) ውስጥ ከሁለት አስርት አመታት በላይ የመሪነት ቦታዎችን ይዘዋል��� በጥርስ ቀዶ ጥገና የዶክትሬት ዲግሪ፣ በሕዝብ ጤና ሁለተኛ ዲግሪንም አግኝታለች። ዶ/ር ብሩስ አይልዋርድ እ.ኤ.አ ከግንቦት 4 ቀን 2023 ጀምሮ የአለም አቀፍ የጤና ሽፋን የህይወት ኮርስ ክፍል ረዳት ዋና ዳይሬክተር ሆነው ተሹመዋል። ዶ/ር አይልዋርድ የአለም ጤና ድርጅት የለውጥ አጀንዳን እና የድርጅቱን የባለብዙ ኤጀንሲ የኮቪድ-19 መሳሪያዎች አፋጣኝ (ACT-A) ሀብን በመምራት ላይ ናቸው። ዶ/ር አይልዋርድ በአዲሱ የሥራ ድርሻው የድርጅቱን አጀንዳ በመንዳት የመጀመሪያ ደረጃ የጤና አገልግሎትን እንደ ማዕከላዊ ወደ ሁለንተናዊ የጤና ሽፋን ለመቀየር እንዲሁም የዓለም ጤና ድርጅት በጤና ስርዓቶች፣ በክትባት እና በስነ-ተዋልዶ፣ በእናቶች እና ህጻናት ጤና ላይ የሚሰራውን ስራ ይቆጣጠራል። ዶ/ር አይልዋርድ የሕክምና ዲግሪ እና የማስተርስ በሕዝብ ጤና ዲግሪ አላቸው። ዶክተር ሃናን ባልኪ የፀረ-ተባይ መከላከያ ረዳት ዋና ዳይሬክተር ሆነው ይቀጥላሉ ዶ/ር ባልኪ ከምግብ እና ግብርና ድርጅት፣ ከዓለም የእንስሳት ጤና ድርጅት እና ከተባበሩት መንግስታት የአካባቢ ጥበቃ ፕሮግራም ጋር ባለ ብዙ ዘርፍ ትብብርን ጨምሮ የመድኃኒት የመቋቋም የጤና እና ኢኮኖሚያዊ ሸክሞችን ለመግታት ቴክኒካል እና ፖለቲካዊ አመራር ይሰጣል። ዶ/ር ባልኪ የዓለም ጤና ድርጅትን ከመቀላቀላቸው በፊት በሳዑዲ አረቢያ ብሔራዊ ጥበቃ ሚኒስቴር የኢንፌክሽን መከላከልና መቆጣጠር ዋና ዳይሬክተር ነበሩ። ዶ/ር ባልኪ በልጆች ተላላፊ በሽታዎች ላይ ልዩ ሙያ ያለው የሕክምና ዲግሪ አለው። ዶ/ር ካታሪና ቦህሜ እ.ኤ.አ ከግንቦት 4 ቀን 2023 ጀምሮ ረዳት ዋና ዳይሬክተር፣ የውጭ ግንኙነት እና አስተዳደር ይሆናሉ። በዚህ ሚና ዶ/ር ቦህሜ የአለም ጤና ድርጅትን ስትራቴጂክ ተሳትፎን በአስተዳደር ፣በሃብት ማሰባሰብ እና የአጋር ግንኙነቶችን ይመራል። የእርሷ የስራ መደብ፣ ወሳኝ የአባል ሀገራት ሂደቶችን ማጠናቀርን ያጠቃልላል፣ ለምሳሌ ስለ ወረርሽኙ ስምምነት ድርድር፣ የአለም ጤና ድርጅት ማሻሻያ እና በዘላቂ ፋይናንስ ላይ ምክሮችን መተግበር ነው። ዶ/ር ቦህሜ የድርጅቱን ስትራቴጂካዊ ራዕይ በመንዳት የድርጅቱ ዋና ዳይሬክተር ጄኔራል ሼፍ ዴ ካቢኔ በመሆን በማገልገል ላይ ትገኝ ነበር።,"Dr Nakatani holds a medical degree and a PhD in public health. Dr Razia Pendse will become the Chef de Cabinet as of 4 May 2023. In this role Dr Pendse will head the Director-General’s Office, helping to drive the Organization’s priorities and initiatives, and will ensure alignment within the WHO leadership team and across the three levels of WHO. Dr Pendse has been serving as the Director of Healthier Populations and Noncommunicable Diseases in the WHO Regional Office for South-East Asia and was previously the WHO Representative to Sri Lanka. Dr Pendse holds a medical degree and master's degree in public health. Dr Jérôme Salomon will become Assistant Director-General for Universal Health Coverage, Communicable and Noncommunicable Diseases as of 17 April 2023. In this role Dr Salomon will oversee a broad portfolio of technical programmes covering HIV, viral hepatitis, sexually-transmitted infections, tuberculosis, malaria, neglected tropical diseases, mental health, substance use disorders, and noncommunicable diseases such as cardiovascular disease, diabetes, chronic respiratory diseases and cancer. Dr Salomon has been serving as the Director-General for Health at the Ministry of Health and Prevention of France. He was a Member of the WHO Executive Board prior to his appointment and has extensive experience in health systems management, communicable diseases and international public health. Dr Salomon holds a medical degree, a master’s degree in public health and a PhD in epidemiology. The portfolios of existing members of the headquarters leadership team: Dr Samira Asma will continue as the Assistant Director-General for Data, Analytics and Delivery for Impact. Dr Asma oversees a portfolio which ensures that health data are reliable and accessible, and are used to improve health outcomes worldwide, including tracking and accelerating progress towards the triple billion targets and the health-related Sustainable Development Goals. Prior to joining WHO in 2018, Dr Asma held leadership positions at the U.S. Centers for Disease Control and Prevention (CDC) for over two decades. She holds a doctorate degree in dental surgery and a master's degree in public health. Dr Bruce Aylward has been appointed Assistant Director-General of the Universal Health Coverage, Life Course Division as of 4 May 2023. Dr Aylward has been leading WHO’s Transformation Agenda and the Organization’s work on the multi-agency Access to COVID-19 Tools Accelerator (ACT-A) Hub. In his new role, Dr Aylward will drive the Organization’s agenda to transform primary health care as central to universal health coverage, as well as overseeing WHO’s work on health systems, immunization and reproductive, maternal and child health. Dr Aylward holds a medical degree and a master’s degree in public health.Dr Hanan Balkhy will continue as Assistant Director-General for Antimicrobial Resistance. Dr Balkhy provides technical and political leadership to curb the health and economic burdens of drug resistance, including through multi-sectoral collaboration with the Food and Agriculture Organization, the World Organization for Animal Health, and the United Nations Environment Programme. Prior to joining WHO, Dr Balkhy was Executive Director for Infection Prevention and Control at Saudi Arabia’s Ministry of National Guard. Dr Balkhy holds a medical degree with specialization in paediatric infectious diseases. Dr Catharina Boehme will become Assistant Director-General, External Relations and Governance as of 4 May 2023. In this role Dr Boehme will lead WHO’s strategic engagement in the areas of governance, resource mobilization and partner relations. Her portfolio will include critical Member States processes, such as their negotiation of a pandemic accord, the reform of WHO’s governance and the implementation of recommendations on sustainable financing. Dr Boehme has been serving as the Director-General’s Chef de Cabinet during which time she drove the leadership’s strategic vision, ensuring alignment across the Organization and with Member States and partners.","Dakta Nakatani yana da digirin farko a ɓangaren likitanci da digirin digirgir a fannin kiwon lafiyar jama'a. Dakta Razia Pendse za ta karɓi matsayin Chef de Cabinet har zuwa 4 ga watan Mayu 2023. A wannan muƙamin, Dakta Pendse zai jagoranci ofishin Darakta-Janar, wanda zai taimaka wajen fitar da fifiko da tsare-tsare na kungiyar, kuma zai tabbatar da daidaito a cikin tawagar shugabannin Hukumar WHO da kuma a cikin matakai uku na WHO. Dakta Pendse ya kasance Daraktan Kula da Lafiyar Jama'a da Cututtukan da ba sa yaɗuwa a Ofishin Hukumar WHO na yankin Kudu maso Gabashin Asiya kuma a baya shi ne Wakilin Hukumar WHO a Sri Lanka. Dakta Pendse yana da digirin farko a ɓangaren likitanci da digirin digirgir a fannin kiwon lafiyar jama'a. Dakta JérÃ'me Salomon zai zama Mataimakin Darakta-Janar na Kula da Lafiya ta Duniya, Cututtuka masu Yaɗuwa da Marasa Yaɗuwa daga ranar 17 ga Afrilu 2023. A wannan muƙamin, Dakta Salomon zai kula da babban fayil na shirye-shiryen fasaha wanda ya shafi cutar ƙanjamau, hepatitis viral, cututtukan da ake kamuwa da su ta hanyar jima'i, tarin fuka, zazzaɓin cizon sauro, cututtuka na wurare masu zafi da ba a kula da su, lafiyar ƙwaƙwalwa, rashin amfani da abubuwa, da cututtukan da ba a iya kamuwa da su kamar cututtukan zuciya da jijiyoyin jini, ciwon sukari, na yau da kullun, cututtuka da suka shafi numfashi da ciwon daji. Dakta Salomon ya kasance babban darakta mai kula da lafiya a ma’aikatar lafiya da rigakafin ƙasar Faransa. Ya kasance memba a hukumar ta WHO kafin naɗin nasa, kuma yana da gogewa a fannin kula da tsarin kiwon lafiya, cututtuka masu yaɗuwa da kuma lafiyar al'ummar duniya. Dokta Salomon yana da digiri na likitanci, digiri na biyu a fannin kula da lafiyar jama'a da kuma digiri na uku a fannin ilimin cututtuka. Takaddun mambobi na ƙungiyar jagoranci na hedkwatar sun haɗa da: Dr Samira Asma wacce za ta ci gaba da zama mataimakiyar Darakta-Janar kan Bayanai, Bincike da Bayarwa don Tasiri. Dokta Asma tana kula da fayil ɗin da ke tabbatar da cewa bayanan kiwon lafiya amintattu ne kuma ana iya samun su, kuma ana amfani da su don haɓaka sakamakon kiwon lafiya a duk duniya, gami da bin diddigin ci gaba da haɓaka ci gaba zuwa buƙatun biliyan uku da maƙasudin ci gaba mai dorewa masu alaƙa da lafiya. Kafin ta fara aikin da Hukumar WHO a shekarar 2018, Dakta Asma ta riƙe muƙaman jagoranci a Cibiyar Kula da Cututtuka ta Ƙasar Amurka (CDC) na sama da shekaru ashirin. Ta yi digirin digirgir a fannin aikin tiyatar haƙori da kuma digiri na biyu a fannin kiwon lafiyar jama'a. An nada Dakta Bruce Aylward a matsayin Mataimakin Darakta-Janar na Kula da Lafiya ta Duniya, Sashen Koyarwa da Rayuwar zamantakewa har zuwa 4 ga watan Mayun 2023. Dakta Aylward ya kasance yana jagorantar Ajandar Sauye-sauye ta Hukumar WHO da kuma ayyukan Ƙungiyar kan Samar da Ma'aikatu da yawa zuwa Cibiyar Haɓaka Kayan aikin cutar COVID-19 (ACT. A wannan sabon muƙamin, Dakta Aylward zai jagoranci ajandar ƙungiyar don canza tsarin kiwon lafiya a matakin farko zuwa matakin gamagari, da kuma tabbatar da tsarin kiwon lafiya na duniya, da kuma kula da ayyukan WHO kan tsarin kiwon lafiya, rigakafi da haihuwa, lafiyar mata. Dakta Aylward yana da digirin likitanci da kuma digiri na biyu a fannin kiwon lafiyar jama'a. Dakta Hanan Balkhy za ta ci gaba da zama mataimakiyar Darakta-Janar ta Antimicrobial Resistance. Dakta Balkhy yana ba da jagoranci na fasaha da siyasa don magance matsalolin lafiya da kuma tsadar magungunan magance ta'ammuli da ƙwayoyi, ciki har da ta hanyar haɗin gwiwar ɓangarori da yawa tare da Hukumar Abinci da Aikin Noma, Hukumar Lafiya ta Duniya, da Hukumar Kula da Muhalli ta Majalisar Ɗinkin Duniya. Kafin shigarsa Hukumar WHO, Da Balkhy ya kasance Babban Darakta na Kariya da Kula da Cututtuka a Ma'aikatar Tsaro ta Ƙasar Saudi Arabiya. Dakta Balkhy yana da digiri a ɓangaren likitanci tare da ƙwarewa a cututtuka masu yaɗuwa a ƙananan yara. Dakta Catharina Boehme za ta zama mataimakiyar Darakta-Janar, Harkokin Ƙetare da Jagoranci tun daga 4 ga watan Mayun 2023. A wannan muƙamin, Dakta Boehme zai jagoranci dabarun Hukumar WHO a fannonin gudanar da mulki, tattara albarkatu da dangantakar abokantaka. Shugabancin nata zai haɗa da kula da matakai masu mahimmanci na ƙasashe membobin, kamar tattaunawarsu game da yarjejeniyar annoba, sake fasalin shugabancin Hukumar WHO da aiwatar da shawarwari kan samar da kuɗaɗe mai ɗorewa. Dokta Boehme ta kasance tana aiki a matsayin Babban Daraktan Chef de Cabinet a lokacin da ta jagoranci dabarun jagoranci, tare da tabbatar da daidaito a cikin Ƙungiyar da tare da Membobin Ƙasashe da abokan tarayya.","Dk Nakatani ana shahada ya matibabu na shahada ya Uzamivu katiak afya ya umma. Dkt Razia Pendse atakuwa mkuu wa Baraza la mawaziri kuanzia tarehe 4 Mei 2023. Katika jukumu hili Dk Pendse ataongoza ofisi ya mkurugenzi mkuu, akisaidia kuendeleza vipaumbele na mipango ya shirika, atahakikisha uwiano ndani ya timu ya uongozi ya WHO na katika ngazi tatu za WHO. Dk Pendse amekuwa mkurugenzi wa idadi ya watu wenye afya bora na magonjwa yasiyoamukiza katika ofisi ya kanda ya WHO ya Kusini Mashsriki mwa Asia na hapo awali alikuwa mwakilishi wa WHO nchini Sri Lanka. Dk Pendse ana shahada ya matibabu na shahada ya uzamili katika afya ya umma. Dkt Jerome Solomon atakuwa mkurugenzi mkuu msaidizi wa huduma ya afya kwa wote, magonjwa yanayoambukiza na yasiyoamukiza kuanzia tarehe 17 Aprili 2023. Katika jukumu hili Dk Solomon atasimamia sehemu kubwa ya Programuza kiufundi zinaohusu VVU, homa ya Ini, Magonjwa ya Zinaa, kifua kikuu, Malaria, magonjwa kitropiki yaliyosahaulika, afya ya akili, matatizo ya matumizi ya dawa na magonjwa yasiyoambukiza kama vile magonjwa ya moyo na mishipa, kisukari, magonjwa sugu ya kupumua na Saratani. Dk Solomon amekuwa akihudumu kama mkurugenzi mkuu wa afya katika wizara ya afya na kinga ya Ufaransa. Alikuwa mjumbe wa Halmashauri kuu ya WHO kabla ya kuteuliwa na ana uzoefu mkubwa katika usimamizi wa mifumo ya afya, magonjwa ya kuambukiza na afya ya kimataifa ya umma. Dk Solomon ana shahada ya matibabu, shahada ya uzamili katika afya ya umma na shahada ya uzamivu katika magonjwa. Nyadhifa za wanachama waliopo wa timu ya uongozi ya makao makuu: Dk Samira Asma ataendelea kuwa mkurugenzi mkuu msaidizi wa Takwimu, uchanganuzi na uwasilishaji wa Athari. Dkt Asma anasimamia idara ambayo inahakikisha kwamba Data ya afya ni ya kuaminika na inapatikana, na inatumiwa kuboresha matokeo ya afya Duniani kote, ikiwa ni pamoja na kufuatilia na kuharakisha maendeleo kuelekea malengo ya Bilioni tatu na malengo ya maendeleo endelevu yanayohusiana na Afya. Kabla ya kujiunga na WHO mwaka 2018, Dk Asma alishikilia nyadhifa za uongozi katika vituo vya Marekani vya kudhibiti na kuzuia magonjwa (CDC) kwa zaidi ya miongo miwili. Ana shahada ya udaktari katika upasuaji wa meno na shahada ya uzamili katika afya ya umma. Dkt Bruce Aylward ameteuliwa kuwa mkurugenzi mkuu msaidizi wa huduma ya afya kwa wote, idara ya kozi ya maisha kuanzia tarehe 4 Mei 2023. Dk Aylward amekuwa akiongoza ajenda ya mabadiliko ya WHO na kazi ya shirika kwenye kitovu cha wakala mbalimbali cha ufikiaji wa vifaa vya kuharakisha zana za UVIKO-19 (ACT-A). Ktika jukumu lake jipya, Dk Aylward ataendesha ajenda ya shirika la kubadilisha huduma ya afya ya msingi kama msingi wa huduma ya afya kwa wote, vilevile kusimamia kazi ya WHO kuhusu mifumo ya afya, chanjo na afya ya uzazi, uzazi na mtoto. Dkt Aylward ana shahada ya udaktari na shahada ya uzamili katika afya ya umma. Dk Balky ataendelea kuwa mkurugenzi mkuu msaidizi wa upinzani wa Antimikrobia. Dk Balkhy hutoa uongozi wa kiufundi na kisiasa ili kupunguza mizigo ya kiafya na kiuchumi ya ukinzani wa Dawa, ikijumuisha kupitia ushirikiano wa sekta mbalimbali na shirika la chakula na kilimo, shirika la afya ya wanyama Duniani, na mpango wa mazingira wa umoja wa mataifa. Kabla ya kujiunga na WHO, Dk Balkhy alikuwa mkurugenzi mtendaji wa kuzuia na kudhibiti maambukizi katika wizara ya walinzi wa kitaifa ya Saudi Arabia. Dk Balkhy ana shahada ya matibabu na utaalamu wa magonjwa ya kuambukiza kwa watoto. Dk Catharina Boehme atakuwa mkurugenzi mkuu msaidizi, mahusiano ya kimataifa na utawala kuanzia tarehe 4 Mei 2023. Katika jukumu hili Dk Boehme ataongoza ushiriki wa kimkakati wa WHO katika maeneo ya utawala, uhamishaji wa rasilimali na uhusiano wa washirika. Jarada lake litajumuisha michakato muhimu ya nchi wanachama, kama vile mazungumzo yao ya makubaliano ya janga, mageuzi ya utawala wa WHO na utekelezaji wa mapendekezo juu ya ufadhili endelevu. Dk Boehme amekuwa akihudumu kama mkuu wa Baraza la mawaziri la mkurugenzi mkuu wakati ambapo aliongoza maono ya kimkakati ya uongozi, kuhakikisha uwiano katika shirika na nchi wanachama na washirika.","Dr Nakatani ní ìwé-ẹ̀rí ìṣẹ̀gun àti PhD nínú ìlera àwùjọ. Dr Razia Pendse máa di Chef de Cabinet láti 4 oṣù Èbìbí ọdún 2023. Nínú ipò yìí Dr Pendse máa di olórí Ọ́fíísì Olùdarí-Àpapọ̀, tí yóò máa ṣe ìrànwọ́ láti darí àwọn nǹkan pàtàkì Àjọ náà àti àwọn ìpilẹ̀ṣẹ̀, yóó sì ṣe àrídájú ìdọ́gba láàrín ikọ̀ àwọn olùdarí WHO àti jákèjádò àwọn ìpele mẹ́tẹ̀ẹ̀ta WHO. Dr Pendse ti ń ṣiṣẹ́ gẹ́gẹ́ bíi Olùdarí fún Àwọn Ènìyàn Tó Ní Àlàáfíà àti Àwọn Ààrùn tí kìí Ràn ní Ọ́fíísì Ẹkùn Agbègbè WHO fún Gúúsù Ìlà-oòrùn Asia tí ó sì jẹ́ Aṣojú WHO ní Sri Lanka tẹ́lẹ̀. Dr Pendse ní ìwé-ẹ̀rí ìṣẹ̀gun àti ìwé-ẹ̀rí másítà nínú ìlera àwùjọ. Dr Jérôme Salomon máa di Igbákejì Olùdarí-Àpapọ̀ fún Kíkárí Ìlera Lágbàyé, Ààrùn Àkóràn àti Ààrùn tí kìí Ràn láti 17 oṣù Igbe ọdún 2023. Nínú ipò yìí Dr Salomon máa ṣàmójútó àwọn ipò àwọn ètò ìmọ̀-ẹ̀rọ tó fẹjú tó kárí KASA, àjàkálẹ̀ ààrùn jẹ̀dọ̀jẹ̀dọ̀, àwọn ààrùn látara ìbálòpọ̀, ikọ́fe, àìsàn ibà, àwọn ààrùn ìgbóná tí wọ́n ti patì, ìlera ọpọlọ, ààrùn ìlòkulò oògùn, àti àwọn ààrùn tí kìí ràn bíi ààrùn ọkàn, àtọgbẹ, ààrùn ọ̀fìnkì tó lágbára àti ààrùn jẹjẹrẹ. Dr Solomon ti ń ṣiṣẹ́ gẹ́gẹ́ bíi Olùdarí-Àpapọ̀ fún Ìlera ní Ilé-iṣẹ́ Ìjọba tó ń rí sí Ètò Ìlera àti Ìdènà fún orílẹ̀-èdè France. Ó jẹ́ ọmọ ẹgbẹ́ Ìgbìmọ̀ Aláṣẹ WHO ṣíwájú ìyànsípò rẹ̀ ó sì ní ìrírí tó pọ̀ nínú àmójútó àwọn ètò ìlera, àwọn ààrùn àkóràn àti ìlera àwujọ ilẹ̀-òkèèrè. Dr Solomon ní ìwé-ẹ̀rí ìṣẹ̀gun, ìwé-ẹ̀rí másítà nínú ìlera àwùjọ àti PhD nínú ẹ̀kọ́ nípa àjàkálẹ̀ ààrùn. Àwọn ipò àwọn ọmọ ẹgbẹ́ tó ṣì wà nínú ikọ̀ olórí olú ilé-iṣẹ́ náà ni: Dr Samira Asma máa tẹ̀síwájú gẹ́gẹ́ bíi Igbákejì Olùdarí-Àpapọ̀ fún Dátà, Ìyànnàná àti Àgbékalẹ̀ fún Ipa. DR Asma ń ṣàmójútó ipò kan tó ń rí i dájú pé àwọn dátà ìlera ṣe é gbáralé ó sì wà fún lílò, wọ́n sì ń lò ó láti mú àyípadà bá àbájáde ìlera jákèjádò àgbáyé, tó fi mọ́ ìtọpinpin àti mímú kí ìtẹ̀síwájú yá fún àwọn àfojúsùn bílíọ̀nù mẹ́ta àti àwọn Èròngbà Ìdàgbàsókè Alálòpẹ́ ajẹmọ́-ìlera. Ṣíwájú kí ó tó darapọ̀ mọ́ WHO ní ọdún 2018, Dr Asma wà ní ipò olórí kan ní Ààyè fún Ìdarí Ààrùn àti Ìdènà (CDC) ní U.S. fún ogún ọdún lé. Ó ní ìwé-ẹ̀rí ọ̀mọ̀wé nínú iṣẹ́ abẹ eyín àti ìwé-ẹ̀rí másítà nínú ìlera àwùjọ. Dr Bruce Aylward ni wọ́n ti yàn sípò gẹ́gẹ́ bíi Igbákejì Olùdarí-Àpapọ̀ fún Kíkárí Ìlera Lágbàyé, Ẹ̀ka Iṣẹ́ Títí Láéláé láti 4 oṣù Èbìbí ọdún 2023. Dr Aylward ti ń darí Ètò Àyípadà WHO àti iṣẹ́ Àjọ náà lórí Ànfààní oríṣiríṣi-àjọ sí Ibùdó àwọn Amúṣiṣẹ́ Irinṣẹ́ COVID-19 (ACT-A). Nínú ipò tuntun rẹ̀, Dr Aylward máa darí ètò Àjọ náà láti mú àyípadà bá àyípadà bá ètò ìlera alábọ́dé gẹ́gẹ́ bíi àárín gbùngbùn fún kíkárí ìlera lágbàyé, bákan náà ni ṣíṣe àmójútó iṣẹ́ WHO lórí àwọn ètò ìlera, abẹ́rẹ́ àjẹsára àti ìlera ìbímọ, ìyá àti ọmọ. Dr Aylward ní ìwé-ẹ̀rí ìṣẹ̀gun àti ìwé-ẹ̀rí másítà nínú ìlera àwùjọ, Dr Hanan Balkhy máa tẹ̀síwájú gẹ́gẹ́ bíi Igbákejì Olùdarí-Àpapọ̀ fún ẹ̀yàwuuru Jáàgùn. Dr Balkhy ń pèsè ìdarí ìmọ̀ ẹ̀rọ àti òṣèlú láti dènà àwọn ìṣòro ìlera àti ọrọ̀ ajé fún jáàgùn, tó fi mọ́ nípasẹ àjọṣepọ̀ pẹ̀lú ẹlẹ́ka-jẹ̀ka pẹ̀lú Ilé-iṣẹ́ Oúnjẹ àti Iṣẹ́ Àgbẹ̀, Àjọ Àgbáyé fún Ìlera Ẹranko, àti Ètò Àwùjọ Àjọ Ìṣọ̀kan Àgbáyé. Ṣíwájú kí ó dó darapọ̀ mọ́ WHO, Dr Balkhy jẹ́ Olùdarí Aláṣẹ fún Ìdènà àti Ìdarí Àkóràn ní Ilé-iṣẹ́ Ìjọba tó ń rí sí Ààbò Orílẹ̀-èdè ní orílẹ̀-èdè Saudi Arabia. Dr Balkhy ní ìwé-ẹ̀rí ìṣẹ̀gun pẹ̀lú àmọ̀já nínú àwọn ààrùn àkóràn ìkókó. Dr Catherina Boehme máa di Igbákejì Olùdarí-Àpapọ̀, Àwọn Àjọṣepọ̀ Láti Ìta àti Ìṣèjọba láti 4 oṣù Èbìbí ọdún 2023. Nínú ipò tuntun yìí Dr Boehme máa léwájú ìlànà-iṣẹ́ ìbáraẹnisọ̀rọ̀ WHO ní àwọn agbègbè ìṣèjọba, ṣíṣe àkójọpọ̀ ohun èlò àti àjọṣe pẹ̀lú àwọn alájọṣepọ̀. Nínú ipò rẹ̀ ni a ti máa rí àwọn ìlànà àwọn Orílẹ̀-èdè Tó Jẹ́ Ọmọ Ẹgbẹ́ tó lágbára, bíi ìdúnàdúrà wọn fún ìṣọ̀kan àjàkálẹ̀ ààrùn, àtúnṣe fún ìṣèjọba WHO àti ṣíṣe àmúlò àwọn àbá lórí ìpèsè owó alálòpẹ́. Dr Boehme ti ń ṣiṣẹ́ gẹ́gẹ́ bíi Olùdarí-Àpapọ̀ Chef de Cabinet ní àkókò tó ṣe wí pé ó darí àfojúsùn ìlànà-iṣẹ́ adarí, ṣíṣe àrídájú ìdọ́gba jákèjádò Àjọ náà àti pẹ̀lú àwọn Orílẹ̀-èdè Tó Jẹ́ Ọmọ Ẹgbẹ́ àti àwọn alájọṣepọ̀.","UDkt Nakatani uneziqu zobudokotela nePhD kwezempilo yomphakathi. UDkt Razia Pendse uzoba nguChef deCabinet kusukela ngomhlaka-4 kuNhlaba 2023. Kulesisikhundla uDkt Pendse uzohola iHhovisi loMqondisi Jikelele, esiza ukuhambisa iNhlangano kokuhamba phambili nemizamo, futhi uzoqinisekisa ukuhambisana neqembu lobuholi beWHO kuwona womathathu amazinga eWHO. UDkt Pendse ubesebenza njengoMqondisi weHealthier Populations and Noncommunicable Diseases kuHhovisi leSifunda leWHO eSouth-East Asia futhi wayemele iWHO eSri Lanka. UDkt Pendse uneziqu zobudokotela neziqu zemastazi kwezempilo yomphakathi. UDkt Jerome Salomon uzoba Ngumsizi waMqondisi Jikelele wezokukhavwa kweZempilo eMhlabeni, izifo okuxhunyanwa ngazo nokungaxhunyanwa ngazo kusukela ngomhlaka-17 Mbasa 2023. Kulesisikhundla uDkt Salamon uzobheka iphothifoliyo enkulu yezinhlelo zezobuchwepheshe ezibheka iHIV, igciwane lehephathithisi, ukuthelelana kwezifo zocansi, isifo sofuba, umalalaeveva, izifo ezidumile ezinganakiwe, ezempilo zengqondo, isifo sokusebenzisa izidakamizwa izifo okungaxhunyanwa ngazo njengezifo zenhliziyo, ushukena, izifo zondendende zokuphefumua kanye nomdlavuza. UDkt Salomon ubesebenza njengoMqondisi Jikelele weZempilo kubungqongqoshe beZempilo nokuvikela eFrance. Wayeyilungu leBhodi labaphathi beWHO ngaphambi kokuqokwa kwakhe futhi nesipiliyoni sakhe esikhulu ekuphathweni kwezinhlelo zempilo,izifo okuxhunyanwa ngazo nezempilo yomphakathi kumazwe angaphandle. UDkt Salomon uneziqu zobudokotela,izqu zemastazi kwezempilo yomphakathi kanye nePHD ku-ephidemiloji. Lamaphothifolo amalungu akhona eqembu lobuholi ekomkhulu: uDkt Samira Asma uzoqhubeka njengoMsizi Mqondisi Jikelele weMininingo, ukuhlaziya nokulethwa kwemithelela. UDkt Asma ubheke iphothifoliyo eqinisekisa ukuthi idatha yezempilo ikhona futhi iyatholakala, futhi isetshenziswa ukwenzangcono imiphumela yezempilo emhlabeni wonke, okufaka ukulandelela nokuqhuba ukuqhubeka okubheke kokuqondiwe okungamabhiliyoni amathathu futhi okuhlobene nesempilo yeSustainable Development Goals. Ngaphambi kokujoyina iWHO ngo-2018, uDkt Asma ubambe izikhundla zobuholi e-U.S. Centers for Disease Contrel and Prevention (CDC) iminyaka engaphezu kwamashumi amabili. Uneziqu zobudokotela kwezokuhlinza amazinyo kanye neziqu kwezempilo yomphakathi. UDkt Bruce Alyward useqokelwe ukuba nguMsizi aMqondisi Jikelele weze-Universal Health Coverage, Life Course Division kusuka ngomhlaka-4 kuNhlaba 2023. UDkt Aylward ubehola iTransformation Agenda yeWHO kanye nomsebenzi wenhlangano kuma-ejensi amaningi okuthola amathuluzi eCOVID-19 okuqhubeka kuhabhu (ACT-A). Kundima yakhe, uDkt Aylward uzohambisa ajenda yeNhlangano yokuguqula ezokunakekelwa kwezempilo kokuqala njengemaphakathi lezokukhavwa kwezempilo emhlabeni kanye nokubheka umsebenzi weWHO wokusebenza kwezinhlelo zempilo, ukugoma, ukuzala, abakhulelwe kanye nezempilo yezingane. UDkt Alyward uneziqu zobudokotela kanye nemastazi yezempilo yomphakathi. UDkt Hanan Balykhy uzoqhubeka nokuba nguMszi waMqondisi Jikelele weAntimicrobial Resistance. UDkt Balkhy uzonikezela ngobuchwepheshe nobuholi bezepolitiki ukubheka ezempilo nomthwalo wezomnotho ekungavumini kwesidakamizwa,okufaka ngokubambisana kwemikhakha eminingi neNhlangano yeZolimo noKudla Inhlangano yoMhlaba yezeMpilo yeZilwane kanye neUnited Nations Environment Programme. Ngaphambi kokujoyina iWHO, uDkt Balkhy ubenguMqondisi omkhulu weWokuvikela ukuthelelana nokulawula eSaudi Arabia Ministry of Nationa Guard. UDkt Balkhy uneziqu zobudokotela nokugxila ezifweni ezithelelanayo ezinganeni. UDkt Catharina Boehme uzoba nguMsizi kaMqondisi Jikelele weExternal Relations and Government kusukela mhlaka-4 kuNhlaba 2023. Kulesisikhundla uDkt Boehme uzohola ukuphathwa kwamasu kweWHO ezindaweni zokuphatha,ukuhlanganisa izinsizakusebenza nobudlelwano bokubambisana. Iphothifoliyo yakhe izofaka ubucayi bohlelo lweMember State, njengokuxoxisana kwabo kusivumelwano sobhubhane, ukwenza kabusha ukubusa kweWHO nokwenza kweziphakamiso ekugcinekeni kwezezimali. UDkt Boehme ubelokhu esebenza njengoMqondisi Jikelele weChef de Cabinet ngaleso sikhathi wahambisa ubuholi kumbono wesu,eqinisekisa ukuhambisana kuzona zonke izinhlangano namaMember State nababambisani."
 እ.ኤ.አ በ2021 የአለም ጤና ድርጅትን ከመቀላቀሏ በፊት፣የ ኤፍ.አይ.ኤን.ዲ(FIND) ዋና ስራ አስፈፃሚ በመሆን፣የአለም አቀፍ ጥምረት መርማሪ ነበረች። ዶ/ር ቦህሜ የህክምና ዲግሪ እና በህዝብ ጤና እና አስተዳደር ዲፕሎማ አግኝተዋል። ዶ/ር ቺክዌ ኢኽክዌዙ በድንገተኛ አደጋ ፕሮግራም ውስጥ የጤና ድንገተኛ መረጃ እና ክትትል ስርዓቶች ክፍል ረዳት ዋና ዳይሬክተር ሆነው ይቀጥላሉ። እንደ ስራ ድርሻው አካልም፣ ዶ/ር ኢክክዋዙ የዓለም ጤና ድርጅትን አለምአቀፋዊ ወረርሽኝ እና ክልላዊ ወረርሽኝ ኢንተለጀንስ ይመራሉ፣ አጋሮችን በማሰባሰብ ወደፊት ስለ ወረርሽኙን እና የወረርሽኙን አደጋዎች በተሻለ የመረጃ ተደራሽነት፣ የትንታኔ አቅም እና የውሳኔ ሰጭ መሳሪያዎች ላይ ይሰራሉ። ዶ/ር ኢሂክዋዙ እ.ኤ.አ ከ2016 እስከ 2021 ድረስ የአለም ጤና ድርጅትን ከመቀላቀላቸው በፊት የናይጄሪያ የበሽታ መቆጣጠሪያ ማዕከል (NCDC) የመጀመሪያው ዋና ዳይሬክተር ነበሩ። ዶ/ር ኢሂክዋዙ የህክምና ዲግሪ አላቸው፣ በልዩ ባለሙያነት እንደ ተላላፊ በሽታ ኤፒዲሚዮሎጂስት እና በሕዝብ ጤና ማስተርስ ዲግሪ አላቸው። ዶ/ር ማይክል ራያን የአለም ጤና ድርጅት(WHO's) የጤና ድንገተኛ አደጋ መርሀ ግብር ዋና ዳይሬክተር ሆነው ይቀጥላሉ። ዶ/ር ራያን በአለም ጤና ድርጅት ውስጥ ላለፉት 25 አመታት የጤና ድንገተኛ አደጋዎችን ሲመሩ የቆዩ ሲሆን በቅርቡም የአለም ጤና ድርጅት ለኮቪድ-19 ወረርሽኝ የድንገተኛ ጊዜ ምላሽን መርተዋል። ለበሽታ ወረርሽኝ፣ ለሰብአዊ ቀውሶች እና ለሌሎች የህዝብ ጤና ድንገተኛ አደጋዎች የዓለም ጤና ድርጅት ምላሽንም ይመራል። ዶ/ር ራያን በአለም ዙሪያ በመቶዎች ለሚቆጠሩ የበሽታ ወረርሽኞች ምላሽ የረዳው የአለም አቀፍ ወረርሽኝ ማስጠንቀቂያ እና ምላሽ መረብ (GOARN) መስራች አባል ነው። ዶ/ር ራያን በህክምና ዲግሪን እና በህዝብ ጤና ሁለተኛ ዲግሪያቸውን አግኝተዋል። ሚስተር ራውል ቶማስ የንግድ ስራዎች ረዳት ዋና ዳይሬክተር ሆነው ይቀጥላሉ። ሚስተር ቶማስ ለ አለም ጤና ድርጅት የንግድ ተግባራት ባጀት፣ ፋይናንስ፣ የሰው ሃይል፣ አስተዳደር፣ ኦዲት፣ የአደጋ አስተዳደር፣ ተጠያቂነት እና ተገዢነት እና አጠቃላይ አስተዳደርን ጨምሮ አጠቃላይ ሃላፊነት አለበት። በድርጅቱ የለውጥ አጀንዳ ውስጥ ያሉትን ብዙ ተነሳሽነቶችን በመተግበር እና የተከበረ፣ ሁሉን አቀፍ የስራ ቦታ የመፍጠር ሃላፊነት አለበት። አቶ ቶማስ ከአለም ጤና ድርጅት ጋር ባሳለፉት 20 አመታት በአፍሪካ፣ በአሜሪካ፣ በምስራቅ ሜዲትራኒያን እና በምዕራብ ፓስፊክ እንዲሁም በአለም አቀፍ የካንሰር ምርምር ኤጀንሲ (IARC) አገልግለዋል። ሚስተር ቶማስ በድርጅት አስተዳደር የማስተርስ ዲግሪ እና በቢዝነስ አስተዳደር የመጀመሪያ ዲግሪ አላቸው።,"She joined WHO in 2021, having been the Chief Executive Officer of FIND, the international alliance for diagnostics. Dr Boehme holds a medical degree and diplomas in public health and management. Dr Chikwe Ihekweazu will continue as Assistant Director-General for the Division of Health Emergency Intelligence and Surveillance Systems in the Emergencies Programme. As part of his portfolio, Dr Ihekweazu leads the WHO Hub for Pandemic and Epidemic Intelligence, bringing together partners to address future pandemic and epidemic risks with better access to data, analytical capacities, and tools for decision-making. Prior to joining WHO, Dr Ihekweazu was the first Director General of the Nigeria Centre for Disease Control (NCDC), from 2016 to 2021. Dr Ihekweazu holds a medical degree, with specialization as an infectious disease epidemiologist, and a master’s degree in public health. Dr Michael Ryan will continue as Executive Director of WHO’s Health Emergencies Programme. Dr Ryan has been managing health emergencies in WHO for the past 25 years and most recently led WHO’s emergency response to the COVID-19 pandemic. He leads WHO’s response to disease outbreaks, humanitarian crises and other public health emergencies. Dr Ryan is a founding member of the Global Outbreak Alert and Response Network (GOARN), which has aided the response to hundreds of disease outbreaks around the world. Dr Ryan holds a degree in medicine and a master’s degree in public health. Mr Raul Thomas will continue as Assistant Director-General for Business Operations. Mr Thomas has overall responsibility for WHO’s business functions, including budget, finance, human resources, administration, audit, risk management, accountability and compliance, and general management. He is responsible for implementing many of the initiatives under the Organization’s transformation agenda and creating a respectful, inclusive workplace. During his 20 years of employment with WHO, Mr Thomas has served in the regions of Africa, the Americas, the Eastern Mediterranean and the Western Pacific, as well as with the International Agency for Research on Cancer (IARC). Mr Thomas holds a master’s degree in organizational management and a bachelor’s degree in business administration.","Ta fara aiki da Hukumar WHO a shekarar 2021, kasancewar ta Babban Jami'ar Gudanarwa na FIND, ƙawancen ƙasa da ƙasa don binciken cututtuka. Dakta Boehme tana da digiri a likitaci da difloma a fannin kiwon lafiyar jama'a da gudanarwa. Dakta Chikwe Ihekweazu zai ci gaba da zama Mataimakin Darakta-Janar na Sashen Nazarin Gaggawa na Lafiya a cikin shirin Tsarin Sa ido na Gaggawa. A matsayin wani ɓangare na aikace-aikace n sa, Dakta Ihekweazu yana jagorantar Cibiyar Hukumar WHO don Cututtuka da haɗo kan masu ruwa da tsaki da abokan haɗin gwiwa don magance annoba da bala'in annoba a nan gaba tare da ingantacciyar damar samun bayanai, damar tantancewa, da kayan aikin da suka dace domin yanke shawarwari. Kafin ya koma Hukumar WHO, Dakta Ihekweazu ya kasance Darakta-Janar na Cibiyar Kula da Cututtuka ta Najeriya (NCDC), daga 2016 zuwa 2021. Dakta Ihekweazu yana da digirin likitanci, tare da ƙwarewa a matsayin likita mai bincike n cututtuka, da kuma digiri na biyu a fannin lafiyar jama'a. Dakta Michael Ryan zai ci gaba da zama Babban Darakta na Shirin Agajin Lafiya na Hukumar WHO. Dakta Ryan yana gudanar da ayyukan gaggawa na lafiya a Hukumar WHO na kimanin shekaru 25 da suka gabata kuma kwanan nan ya jagoranci matakin gaggawa na Hukumar WHO game da cutar mashaƙon numfashi wato COVID-19. Yana jagorantar martanin Hukumar WHO game da ɓarkewar cututtuka, rikice-rikicen jin ƙai da sauran abubuwan gaggawa na lafiyar jama'a. Dakta Ryan na ɗaya daga cikin mambobin farko na ƙungiyar da ta kafa wata ƙungiya mai suna Global Outbreak Alert and Response Network (GOARN), wacce ta taimaka wajen mayar da martani ga ɗaruruwan ɓullar cututtuka a duniya. Dakta Ryan yana da digirin farko a fannin likitanci da kuma digiri na biyu a fannin lafiyar jama'a. Mista Raul Thomas zai ci gaba da zama Mataimakin Darakta Janar na Ayyukan Kasuwanci. Mista Thomas yana da cikakken alhakin ayyukan kasuwanci na Hukumar WHO, gami da kasafin kuɗi, yawan ma'aikata, gudanarwa, binciken gujewa haɗari, lissafi da bin doka, da gudanarwa gabaɗaya. Shi ne ke da alhakin aiwatar da yawancin tsare-tsare a ƙarƙashin ajandar canji na Ƙungiya da ƙirƙirar wurin aiki mai mutuntawa da kuma haɗin kan aiki. A tsawon shekaru 20 da ya yi yana aiki tare da Hukumar WHO, Mista Thomas ya yi aiki a yankunan Afirka, Amurka, Gabashin Bahar Rum da Yammacin Pacific, da kuma Hukumar Bincike kan cutar daji(IARC). Mista Thomas yana da digiri na biyu a fannin sarrafa ƙungiyoyi da digiri na farko a fannin gudanar da kasuwanci.","Alijiunga na WHO mnamo 2021, akiwa Afisa mkuu mtendaji wa FIND, muungano wa kimataifa wa uchunguzi. Dk Boehme ana shahada ya matibabu na Stashahada katika afya ya umma na usimamizi. Dk Chikwe Ihekweazu ataendelea kuwa mkurugenzi mkuu msaidizi wa kitengo cha mifumo ya upelelzi wa dharura ya kiafya na ufuatiliaji katika mpango wa dharura. Kama sehemu ya jalada lake, Dk Ihekweazu anaongoza kitovu cha WHO cha ujasusi wa ugonjwa wa mlipuko na milipuko, akiwaleta pamoja washirika kushughulikia hatari za janga na magonjwa ya siku siku zijazo na ufikiaji bora wa Data, uwezo wa uchambuzi, na zana za kufanya maamuzi. Kabla ya kujiunga na WHO, Dk Ihekweazu alikuwa mkurugenzi mkuu wa kwanza wa kituo cha kudhibiti magonjwa cha Nigeria (NCDC), kuanzia 2016 hadi 2021. Dk Ihekweazu ana shshada ya matibabu, na utaalamu kama mtaalamu wa magonjwa ya kuambukiza, na shahada ya uzamili katika afya ya umma. Dtk Michael Ryan ataendelea kama mkurugenzi mtendaji wa mpango wa dharura wa afya wa WHO. Dk Ryan amekuwa akisimamia dharura za kiafya katika WHO kwa miaka 25 iliyopita na hivi karibuni aliongoza makabiliano ya dharura ya WHO kwa janga la UVIKO-19. Anaongoza muitikio wa WHO kwa milipuko ya magonjwa, majanga ya kibinadamu na dharura nyingine za afya ya umma. Dk Ryan mwanachama mwanzilishi wa mtandao wa tahadhari na makabiliano ya mlipuko wa ulimwenguni (GOARN), ambao umesaidia kukabiliana na mamia ya milipuko ya magonjwa kote ulimwenguni. Dk Ryan ana shahada ya udaktari na shahada ya uzamili katika afya ya umma. Bw Raul Thomas ataendelea kuwa mkurugenzi mkuu msaidizi wa uendeshaji Biashara. Bw. Thomas ana wajibu wa jumla wa kazi biashara za WHO, ikiwa ni pamoja na bajeti, fedha, rasilimali watu, utawala, ukaguzi, usimamizi wa hatari, uwajibikaji na utii, na usimamizi wa jumla. Ana jukumu la kutekeleza mipango mingi chini ya ajenda ya mabadiliko ya shirika na kuunda mahali pakazi pa heshima na jumuishi. Katika miaka yake 20 ya ajira na WHO, Bw Thomas amehudumu katika kanda za Afrika, Mashariki ya Mediterania na Pasifiki Magharibi, vilevile shirika la kimataifa la utafiti wa saratani (IARC). Bw. Thomas ana shahada ya uzamili katika usimamizi wa shirika na shahada ya awali katika usimamizi wa Biashara.","Ó darapọ̀ mọ́ WHO ní ọdún 2021, lẹ́yìn tí ó ti jẹ́ Olórí Àwọn Òṣìṣẹ́ fún FIND, ìṣọ̀kan ilẹ̀-òkèèrè fún àyẹ̀wò fún idámọ̀ ààrùn. Dr Boehme ní ìwé-ẹ̀rí ìṣẹ̀gun àti dípúlómà nínú ìlera àwùjọ àti àmójútó. Dr Chikwe Ihekweazu máa tẹ̀síwájú gẹ́gẹ́ bíi Igbákejì Olùdarí-Àpapọ̀ fún Ẹ̀ka fún Àwọn Ètò Ìmọ̀ Ìlera Pàjáwírì àti Ìtọpinpin nínú Àwọn Èto Pàjáwírì. Gẹ́gẹ́ bí ọ̀kan lára ipò rẹ̀, Dr Ihekweazu máa léwájú Ibùdó WHO fún Àjàkálẹ̀ Ààrùn àti Ìmọ̀ Àjàkálẹ̀ Ààrùn Káríayé, ṣíṣe àkójọpọ̀ àwọn alájọṣepọ̀ láti kojú àwọn ewu àjàkálẹ̀ ààrùn àti àjàkálẹ̀ ààrùn káríayé lọ́jọ́ iwájú pẹ̀lú ànfààní tó dára sí dátà, àwọn ìkápá ìyànnàná, àti àwọn irinṣẹ́ fún ìpinnu-ṣíṣe. Ṣíwájú kí ó tó darapọ̀ mọ́ WHO, Dr Ihekweazu ni Olùdarí Àpapọ̀ àkọ́kọ́ fún Ààyè fún Ìdènà Ààrùn ní orílẹ̀-èdè Nigeria (NCDC), láti ọdún 2016 sí 2021. Dr Ihekweazu ní ìwé-ẹ̀rí ìṣẹ̀gun, pẹ̀lú àmọ̀já gẹ́gẹ́ bíi onímọ̀ nípa àjàkálẹ̀ ààrùn ààrùn àkóràn, àti ìwé-ẹ̀rí másítà nínú ìlera àwùjọ. Dr Michael Ryan máa tẹ̀síwájú gẹ́gẹ́ bíi Olùdarí Aláṣẹ fún Ètò Pàjáwírì Ìlera WHO. Dr Ryan ti ń ṣàmójútó àwọn pàjáwírì ìlera ní WHO láti bíi ọdún 25 sẹ́yìn àti ti àìpẹ́ yìí tó léwájú ìdáhùn pàjáwírì WHO sí àjàkálẹ̀ ààrùn COVID-19. Ó léwájú ìdáhùn WHO sí ìtànkálẹ̀ ààrùn, àwọn rògbòdìyàn ọmọnìyàn àti àwọn pàjáwírì ìlera àwùjọ mìíràn. Dr Ryan jẹ́ ọ̀kan lára àwọn ọmọ ẹgbẹ́ olùdásílẹ̀ Ìfitóni Ìtànkálẹ̀ Ààrùn Àgbáyé àti Ojú Òpó Ìdáhùn (GORAN), tí ó ti ṣe ìrànlọ́wọ́ fún ìdáhùn sí ọgọ́run lé ìtànkálẹ̀ ààrùn jákèjádò àgbáyé. Dr Ryan ní ìwé-ẹ̀rí nínú ìṣẹ̀gun àti ìwé-ẹ̀rí másítà nínú ìlera àwùjọ. Mr Raul Thomas máa tẹ̀síwájú gẹ́gẹ́ bíi Igbákejì Olùdarí-Àpapọ̀ fún Àwọn Iṣẹ́ Òkòwò. Mr Thomas ní àpapọ ojúṣe fún àwọn iṣẹ́ okòwò WHO, tó fi mọ́ ètò ìṣúná, ìpèsè owó, àwọn òṣìṣẹ́, ìṣàkóso, àyẹ̀wò owó, àmójútó ewu, ìṣirò àti ìtẹ̀lé, àti ìṣàmójútó lápapọ̀. Òun ló ṣokùnfà fún ṣíṣe àmúlò ọ̀pọ̀lọpọ̀ àwọn ìpilẹ̀ṣẹ̀ lábẹ́ ètò àyípadà Àjọ náà àti pípèsè ibi-iṣẹ́ tí ọ̀wọ́ wà, àti aláfibọ̀. Ní àkókò 20 ọdún iṣẹ́ rẹ̀ pẹ̀lú WHO, Mr Thomas ti ṣiṣẹ́ ní àwọn ẹkùn agbègbè ilẹ̀ Adúláwọ̀, àwọn America, Eastern Mediterranean àti Western Pacific, bákan náà ni Ilé-iṣẹ́ Ilẹ̀-òkèèrè fún Ìwádìí àti ààrùn Jẹjẹrẹ (IARC). Mr Thomas ní ìwé-ẹ̀rí másítà nínú ìṣàkóso ilé-iṣẹ́ àti ìwé-ẹ̀rí báṣẹ́lọ̀ nínú ìṣàkóso okòwò.","Ujoyine iWHO ngo-2021, ubelokhu enguChief Executive Officer weFIND, owezobudlelwane bamazwe angaphandle kwezokuxilonga. UDkt Boehme uneziqu zobudokotela nediploma ekuphatheni nezempilo yomphakathi. UDKt chikwe Ihekweazu uzoqhubeka nokuba nguMszi waMqondisi Jikelele weDivision of Health Emergency Interlligence and Survillance Systems kuHlelo lwezokuohuthumayo. Njengengxenye yephothifoliyo yakhe, uDkt Ihekweazu uhola iHabhu yeWHO yePandemic and Epidemic Intelligence, ukuhlanganisa ndawonye ababambisani ukubhekana nobhubhane lwekusasa nezingcuphe ze-ephidemikhi ngokungena kangcono kumininingo amandla okuhlaziya namathuluzi okuthatha izinqumo. Ngaphambi kokujoyina iWHO uDkT Ihekweazu waba nguMqondisi Jikelele wokuqala weNigeria Centre fo Disease Control NCDC) kusuka ngo-2016 kuya ku-2021. UDkt Ihekweazu uneziqu zobudokotela ngokugxila ku-ephidomoloji yezifo ezithelelanayo kanye neziqu zemastazi kwezempilo yomphakathi. UDkt Michael Ryan uzoqhubeka nokuba nguMqondisi omkhulu woHlelo lweZiphuthumayo zeMpilo kuWHO. UDkt Ryan ubephethe ezokuphuthumayo zezempilo kuWHO eminyakeni engu-25 eyedlule futhi usanda kuhola ukuphendula kweziphuthumayo kweWHO ngokobhubhane lweCOVID-19. Uhola ukuphendula kweWHO ekubhedukeni kwezifo izinkinga zabantu kanye nokunye ukuphuthuma kwezempilo yomphakathi. UDkt Ryan uyilungu elingumsunguli leGlobal Outbreak Alert and Response Network (GOARN) esisize ukuphendula kumakhulu okubheduka kwezifo emhlabeni wonke. UDkt Ryan uneziqu kwezobudokotela kanye neziqu zemastazi kwezempilo yomphakathi. UMnumzane Raul Thomas uzoqhubeka njengoMsizi waMqondisi Jikelele weZokusebenza zamaBhizinisi. UMnumzane Thomas unomsebenzi wonke wokusebenza kwebhizinisi leWHO, okufaka uhlelomali, ezezimali, ezokusebenza zabantu, ukuphatha, ukucwaninga, ukuphatha ingcuphe, ukuzibophezela nokulandela kanye nokuphatha okujwayelekile. Umsebenzi wakhe ukwenza imizamo eminingi ngaphansi koguquko lwenhlangano nokwenza indawo yokusebenza ehloniphekayo. Ngesikhathi seminyaka yakhe engu-20 esebenza neWHO uMnumzane Thomas usesebenze kuzifunda zase-Afrika, e-Americas kanye nase-Eastern Mediterranean neWestern Pacific kanye ne-International Agency for Research on Cancer (IARC). UMnumzane Thomas uneziqu ze-master ekuphathweni kwenhlangano kanye neziqu ze-bachelor ekuphathweni kwebhizinisi."
-የዓለም ጤና ድርጅት ሙያዊ አማካሪ ቡድን በኮቪድ-19 የክትባት ቅንብር (TAG-CO-VAC) እ.ኤ.አ በመጋቢት 16-17 2023 የተካሄደው ስብሰባ ዘገባ። እ.ኤ.አ. በሰኔ 2022 በኮቪድ 19 ክትባት ላይ የሚሰራው አማካሪ ቡድን ጊዜያዊ መግለጫ ሰጥቷል፤ በዋናው ቫይረስ ላይ የተመሰረቱ ክትባቶች አሁንም ኦሚክሮንን (የኮቪድ 19 ዝርያ) ጨምሮ በሁሉም የኮሮና ቫይረስ አይነቶች ከሚመጡ ከባድ በሽታዎች ከፍተኛ የመከላከል አቅም እንደሚሰጡ አሳይቷል። ነገር ግን፣ ከተጨማሪ የቫይረሱ ዝግመተ ለውጥ አንቲጂኒክ ርቀት እና እርግጠኛ አለመሆን አንፃር፣ TAG-CO-VAC በመረጃ ጠቋሚ ቫይረስ ላይ የተመሰረቱ ክትባቶች ከጊዜ ወደ ጊዜ እየቀነሰ እንደሚሄድ ተገንዝቧል። በኮቪድ 19 ክትባት ላይ የሚሰራው አማካሪ ቡድን የክትባት አምራቾች እና የቁጥጥር ባለስልጣናት ኦሚክሮንን ( Omicron) በግምት ውስጥ በማስገባት የክትባት ቀመሩን ስብጥር ማሻሻያ እንዲያደርጉ መክሯል፤ ይህም እስከ አሁን ድረስ ካሉ የኮሮና ቫይረስ አይነቶች በጣም ልዩ የሆነዎን ኦሚክሮንን እንደ ማበልጸጊያ በመጠቀም ነው። በርካታ የክትባት ሰሪዎች የኮቪድ-19 ክትባቶችን ከተሻሻለ ቀመር ፈጥረዋል፤ ይህ የመጀመሪያውን ቫይረስ እና ቀደምት የኦሚክሮን አይነቶችን (እንደ ኢንዴክስ ቫይረስ + BA.1 ወይም BA.4/5) ሁለቱንም የያዙ mRNA ክትባቶችን ያካትታል፤ እነዚህ ክትባቶች በተቆጣጣሪ አካላት ለድንገተኛ ጊዜ ጥቅም ላይ እንዲውሉ ተፈቅዷል። እ.ኤ.አ በ16-17 2023፣ TAG-CO-VAC በሙስካት፣ ኦማን ውስጥ እንደገና ተሰበሰበ። የስብሰባው ዓላማ ሁለት ነበር፡. የኦሚክሮን የዘር ሀረጎችን እንደ ተጨማሪ መጠን የሚያካትቱ የዘመኑ የኮቪድ-19 ክትባቶች አፈጻጸም ላይ ያለውን ማስረጃ ለመገምገም፣ እና እ.ኤ.አ. በ2023 የኮቪድ 19 ክትባት ስብጥር መመሪያዎችን የሚወጡበትን ጊዜ ለመወሰን። የኦሚክሮን( Omicron) የዘር ሀረጎችን ያካተቱ የተሻሻሉ የኮቪድ-19 ክትባቶችን አፈጻጸም ለመገምገም በTAG-CO-VAC የተገመገመ ማስረጃ፡- (1) BA.1 ወይም BA.4/5 የያዙ ክትባቶች የበሽታውን ምልክቶች እና የተባባሰ የበሽታውን ደረጃ ከማከም አንጻር ምን ያህል ውጤታማ እንደሆኑ የሚገመግሙ የታተሙ ጥናቶች፤ (2) BA.1 ወይም BA.4/5 የያዙ ክትባቶች የመጀመሪያው ቫይረስ ላይ ተመስርተው ከተሰሩ ክትባቶች ጋር ሲነጻጸሩ በተለያዩ የኮሮና ቫይረስ ዝርያዎች ላይ ምን ያህል ውጤታማ እንደሆኑ የሚያሳይ የላብራቶሪ መረጃ፤ (3) የላቦራቶሪ-ተኮር ጥናቶች እና የበሽታ ተከላካይ ማህደረ ትውስታ ምላሾች ላይ ምልከታ ውሂብ በተደጋጋሚ አንቲጂን መጋለጥ በክትባት-መከላከያ እና ጥበቃ ላይ ያለውን ተጽእኖ ለመገምገም. በኮቪድ 19 ክትባት ላይ በሚሰራው አማካሪ ቡድን የተገመገሙ ማስረጃዎች ላይ ተጨማሪ ዝርዝሮችን በአባ��ው ውስጥ ይገኛሉ። ከላይ በተገለጸው መረጃ ግምገማ ላይ በመመስረት፣ TAG-CO-VAC የሚከተለውን ይደመድማል፡- በቫይረስ ኢንዴክስ ላይ የተመሰረቱ ክትባቶችን ከፍ ማድረግ በሁሉም SARS-CoV-2 ልዩነቶች ምክንያት ከሚመጣው ከባድ በሽታ እና ሞት የወቅቱ የኦሚክሮን የዘር ሐረግን ጨምሮ ከፍተኛ ጥበቃ መስጠቱን ቀጥሏል። በመረጃ ጠቋሚ ቫይረስ ላይ የተመሰረቱ ክትባቶች እና BA.1- ወይም BA.4/5-የያዙ bivalent mRNA ክትባቶች ከሚያስከትላቸው ከከባድ በሽታ እና ምልክታዊ ኢንፌክሽን መከላከል በጊዜ ሂደት እየቀነሰ ይሄዳል። ነገር ግን ከከባድ በሽታ መከላከል ምልክታዊ ኢንፌክሽን ከመከላከል ይልቅ ረዘም ላለ ጊዜ ይቆያል. በመጀመሪያው የቫይረስ አይነት ላይ ከተመረኮዙ ክትባቶች ጋር ሲነጻጸር BA.1 ወይም BA.4/5 የያዙ ክትባቶች የኮሮና ህመም ምልክት የሚያሳዩ ሰዎች ላይ ያላቸው ውጤታማነት በጥቂቱ የተሻለ ነው፤ ይሁን እንጂ ከበድ ያለ የበሽታው ደረጃ ላይ በደረሱ ሰዎች ላይ የተደረጉት ጥቂት ጥናቶች እንደሚያሳዩት ተመሳሳይ ውጤታማነት አላቸው። ሁለቱም BA.1 እና BA.4/5 የያዙ ማበልፀጊያ ክትባቶች በመጀመሪያው የቫይረሱ አይነት ላይ ተመስርተው ከተሰሩ ክትባቶች ጋር ሲነፃፀሩ በተለያዩ የኮሮና ቫይረስ ዓይነቶች ላይ የተሻለ አቅም እንዳላቸው ያሳያሉ። BA.4/5 የያዙ ክትባቶች የኦሚክሮን (Omicron ) (BQ.1፣ XBB.1) የኮሮና ቫይረስ አይነትን በመከላከል ረገድ BA.1 ከያዙ ክትባቶች ጋር ሲነፃፀሩ የተሻለ አቅም አላቸው ።,"Report of the meeting of the WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) held on 16-17 March 2023 In June 2022, the TAG-CO-VAC published an interim statement highlighting that index virus-based vaccines continued to confer high levels of protection against severe disease caused by all SARS-CoV-2 Variants of Concern (VOCs), including Omicron. However, given the antigenic distance and uncertainties of further viral evolution, the TAG-CO-VAC recognized that it was likely that the effectiveness of vaccines based on the index virus would reduce over time. The TAG-CO-VAC therefore advised vaccine manufacturers and regulatory authorities to consider an update of vaccine antigen composition by including Omicron, as the most antigenically distinct SARS-CoV-2 variant thus far, for administration as a booster dose. Multiple vaccine manufacturers have developed COVID-19 vaccines with an updated antigenic composition; this includes several bivalent mRNA-based vaccines containing earlier Omicron descendent lineages, in addition to the index virus (i.e., index virus + BA.1 or BA.4/5), which have been authorized for emergency use by regulatory authorities. On 16-17 March 2023, the TAG-CO-VAC reconvened in Muscat, Oman. The purpose of the meeting was two-fold: to review the evidence on the performance of updated COVID-19 vaccines that incorporate descendent lineages of Omicron as a booster dose; and to establish timelines for COVID-19 vaccine composition recommendations in 2023. The evidence reviewed by the TAG-CO-VAC to assess the performance of updated COVID-19 vaccines that incorporated descendent lineages of Omicron included: (1) published observational epidemiological studies of estimates of absolute and relative vaccine effectiveness of BA.1- or BA.4/5-containing bivalent mRNA vaccines used as a booster dose against symptomatic and severe disease; (2) laboratory-based data on the magnitude and breadth of cross-reactive immune responses against previous and circulating SARS-CoV-2 variants induced by BA.1- or BA.4/5- containing mRNA vaccines, as compared to index virus-based vaccines, used as a booster dose; and (3) laboratory-based studies and observational data on immune memory responses to evaluate the impact of repeated antigen exposure on vaccine-induced immunity and protection. Further details on the evidence reviewed by the TAG-CO-VAC can be found in the accompanying annex. Based on the review of the data described above, the TAG-CO-VAC concludes: Booster doses of index virus-based vaccines continue to confer high levels of protection against severe disease and death caused by all SARS-CoV-2 variants, including contemporary Omicron descendent lineages. Protection from severe disease and symptomatic infection induced by index virus-based vaccines and BA.1- or BA.4/5-containing bivalent mRNA vaccines declines over time. However, protection from severe disease is maintained longer than protection from symptomatic infection. As compared to index virus-based vaccines, booster doses of BA.1- or BA.4/5-containing bivalent mRNA vaccines may modestly increase vaccine effectiveness against symptomatic disease, while the small number of studies assessing severe outcomes show similar estimates of vaccine effectiveness. Both BA.1- and BA.4/5-containing bivalent mRNA vaccines enhance the magnitude and elicit greater breadth of cross-reactive immune responses to SARS-CoV-2 variants when used as a booster dose, as compared to the index virus-based vaccines. BA.4/5-containing bivalent mRNA vaccines induced higher neutralizing antibody titres against recent descendent lineages of Omicron (BQ.1, XBB.1) as compared to BA.1-containing bivalent mRNA vaccines, when used as a booster dose.","Rahoton taron Ƙungiyar Ba da Shawarwari na Fasaha ta Hukumar WHO kan Tsarin rigakafin cutar COVID-19 (TAG-CO-VAC) wanda aka gudanar a ranakun 16-17 ga watan Maris 2023 A cikin watan Yunin 2022, TAG-CO-VAC ta buga wata sanarwa ta wucin gadi wacce ke nuna cewa allurar rigakafin ƙwayoyin cutar sun ci gaba da ba da babban matakan kariya daga mummunan cutar da duk SARS-CoV-2 Variants of Concern (VOCs) ke haifarwa, gami da Omicron. Duk da haka, idan aka yi la'akari da sinadarin daidaita garkuwar jiki, an gano cewar akwai rashin tabbas akan cewar allurar Rigakafin TAG-CO-VAC zai cigaba da tasiri bayan wani ɗan lokaci. A don haka masu bayar da shawarwari akan TAG-CO-VAC ta shawarci masu ƙera alluran rigakafi da hukumomin da ke kula da su, da a su yi la’akari da sabunta sinadaran da ke tattare da maganin rigakafi ta hanyar haɗawa da sinadarin Omicron, a matsayin sa na sinadari mafi ƙarfi wajen yaƙar duk wasu nau'ukan cutar SARS-CoV-2 a matsayin maganin samar da kuzari. Masu ƙera alluran rigakafi da yawa sun haɓaka rigakafin COVID-19 tare da sabunta abubuwan antigenic; wannan ya haɗa da alluran rigakafin mRNA da yawa waɗanda ke ƙunshe da nau'ukan Omicron na farko, ban da ƙwayar cuta mai ƙididdigewa (watau ƙwayar cuta + BA.1 ko BA.4/5), waɗanda hukumomin gudanarwa suka bayar da izini don amfanin gaggawa dasu. A ranakun 16-17 ga watan Maris ɗin 2023, kwamitin TAG-CO-VAC ya sake zama a Muscat, wato babban birnin ƙasar Oman. Maƙasudin taron ya kasu kashi biyu: Domin sake nazarin shaida kan ayyukan sabbin rigakafin cutar COVID-19 waɗanda suka haɗa nau'ukan sinadarin Omicron a matsayin sinadarin ƙarin kuzari Domin kafa jadawalin lokaci don shawarwarin haɗa magungunan rigakafin COVID-19 a cikin shekarar 2023. Shaidar nazarin da kwamitin TAG-CO-VAC ta sake dubawa don tantance ayyukan sabbin rigakafin cutar COVID-19 waɗanda suka haɗa nau'ukan Omicron sun haɗa da: (1) An wallafa nazarin cututtukan lura da ƙididdiga na cikakkiyar tasirin maganin rigakafi na BA.1- ko BA.4/5 mai ɗauke da bivalent mRNA alluran rigakafin da aka yi amfani da su a matsayin masu ƙara kuzari akan alamun bayyanar cututtuka da cuta mai tsanani; (2) Bayanan da aka samu akan ɗakin gwaje-gwaje kan girma da faɗin martanin rigakafin na gaba da yaɗuwa da cututtuka mabanbanta masu alaƙa da cutar SARS-CoV-2 waɗanda BA.1- ko BA.4/5- na ɗauke da allurar mRNA, idan aka kwatanta da ƙwayar cuta ta index idan aka kwatanta su da maganin rigakafin da ake amfani da su a matsayin masu ƙara kuzari (3) Nazarin ɗakin gwaje-gwaje da bayanan lura da martanin ƙwaƙwalwar ajiyar rigakafi don kimanta tasirin maimaitawar antigen akan rigakafi da kuma irin kariya da take samarwa. Ana iya samun ƙarin cikakkun bayanai kan shaidar da kwamitin TAG-CO-VAC tayi nazari akai a cikin wasu kundi na nan daba. Dangane da bitar bayanan da aka kwatanta daga farko, kwamitin TAG-CO-VAC ya yanke shawarar: Ƙara yawan allurai na tushen ƙwayoyin cuta suna ci gaba da ba da manyan matakan kariya daga mummunan cutar da rasa rayuka waɗanda duk cututtuka mabanbanta na nau'ukan cutar SARS-CoV-2 suka haifar, gami da nau'ukan sinadarin Omicron na tsawon lokaci. Kariya daga cututtuka masu tsanani da kamuwa da cutar ke haifarwa ta hanyar alluran rigakafin ƙwayoyin cuta da BA.1- ko BA.4/5 mai ɗauke da bivalent mRNA na raguwa akan lokaci. Duk da haka, ana samun kariya daga cututtuka mai tsanani fiye da kariyar da ake samu daga cututtuka masu saurin yaɗuwa. Idan aka kwatanta da alluran rigakafi na tushen ƙwayoyin cuta, masu haɓaka allurai na BA.1- ko BA.4/5-mai ɗauke da bivalent mRNA alluran rigakafi na iya haɓaka tasirin alluran rigakafi a kan bayyanar cututtuka, yayin da ƙaramin adadin binciken da ke tantance sakamako mai tsanani yana nuna ƙididdiga iri ɗaya na rigakafin. Sinadaran BA.1- da BA.4/5-masu ɗauke da bivalent mRNA na alluran rigakafin suna haifar da mafi girman martanin rigakafi ga cututtuka mabambanta nau'ukan SARS-CoV-2 a lokacin da aka yi amfani da su wajen ƙarin kuzari, idan aka kwatanta da ƙwayar cutar tushen alluran rigakafi. BA.4/5 mai ƙunshe da alluran rigakafin mRNA na bivalent sun haifar da mafi girma daidaiton titres antibody a kan kwanan nan na nau'ukan Omicron (BQ.1, XBB.1) idan aka kwatanta da BA.1-ɗauke da bivalent mRNA alluran rigakafi, lokacin da aka yi amfani da matsayin mai ƙara kuzari.","Ripoti ya mkutano wa kikundi cha ushauri wa kiufundi cha WHO kuhusu muundo wa chanjo ya UVIKO-19 (TAG-CO-VAC) uliofanyika tarehe 16-17 Machi 2023. Mnamo Juni 2022, TAG-CO-VAC ilichapisha taarifa ya muda inayoangazia kwamba Chanjo zinazotegemea virusi ziliendelea kutoa viwango vya juu vya ulinzi dhidi ya ugonjwa mbaya unaosababishwa na aina zote za kujali za SARS-CoV-2 (VOCs), pamoja na Omicron. Hata hivyo, kwa kuzingatia umbali wa Antijeni na kutokuwa na uhakika wa mageuzi zaidi ya Virusi, TAG-CO-VAC ilitambua kuwa kuna uwezekano kwamba ufanisi wa chanjo kulingana na virusi vya index ungepungua kwa muda. Hivyo TAG-CO-VAC iliwashauri watengenezaji chanjo na mamlaka za udhibiti kuzingatia sasisho la muundo wa chanjo ya Antijeni kwa kujumuisha Omicron, kama kibadala tofauti kabisa cha SARS-CoV-2 kufikia sasa, kwa matumizi kama Dozi ya nyongeza. Watengenezaji wengi wa chanjo wametengeneza chanjo za UVIKO-19 zilizo na muundo mpya wa Antijeni; hii hujumuisha chanjo kadhaa zenye msingi wa mRNA zenye nasaba za awali za kizazi cha Omicron, pamoja na virusi vya index (yaani; virusi vya index + BA.1 au BA. 4/5, ambazo zimeidhinishwa kwa matumizi ya dharura na mamlaka ya udhibiti. Tarehe 16-17 Machi 2023, TAG-CO-VAC ilikutana tena huko Maskati, Omani. Madhumuni ya mkutano yalikuwa mawili: Kukagua ushahidi kuhusu utendaji kazi wa chanjo zilizosasishwa za UVIKO-19 ambazo zinajumuisha ukoo wa Omicron kama Dozi ya nyongeza; na Ili kuweka ratiba za mapendekezo ya muundo wa chanjo ya UVIKO-19 mwaka 2023. Ushahidi ulikaguliwa na TAG-CO-VAC ili kutathmini utendaji kazi kwa chanjo zilizosasishwa za UVIKO-19 ambazo zilijumuisha ukoo wa Omikroni pamoja na; (1)ilichapisha uchunguzi wa uchunguzi wa magonjwa ya makadirio ya ufanisi kamili na jamaa wa chanjo za BA.1 - au BA. 4/5 - zenye mRNA yenye bivalent zinazotumiwa kama kipimo cha nyongeza dhidi ya ugonjwa wa Symptomatic na kali; (2) Data inayotokana maabara juu ya ukubwa na upana wa mwitikio wa kinga dhidi ya vibadala vya awali na vinavyozunguka vya SARS-CoV-2 vilivyochochewa na chanjo za BA.1- au BA. 4/5- zenye mRNA, ikilinganishwa na chanjo zenye w virusi, kutumika kama kipimo cha nyongeza; na (3) Tafiti zinazotegemea maabara na Data ya uchunguzi kuhusu majibu ya kumbukumbu ya kinga ili kutathmini athari ya kukabiliwa na Antijeni mara kwa mara kwenye kinga na ulinzi unaotokana na chanjo. Maelezo zaidi juu ya ushahidi uliopitiwa na TAG-CO-VAC yanaweza kupatikana katika kiambatisho kinachoambatana. Kulingana na ukaguzi wa Data iliyoelezewa hapo juu, TAG-CO-VAC inahitimisha: Dozi ya nyongeza na chanjo zenye msingi wa virusi vya index zinaendelea kutoa viwango vya juu vya ulinzi dhidi ya ugonjwa mbaya na kifo kinachosababishwa na anuwai zote za SARS-CoV-2, ikijumuisha nasaba za kizazi za kisasa za Omicron. Ulinzi dhidi ya ugonjwa mkali na maambukizi ya Symptomatic yanayotokana na chanjo za virusi vya index na BA.1- au BA. 4/5- zenye bivalent mRNA chanjo hupungua baada ya muda. Hata hivyo, ulinzi kutoka kwa ugonjwa mbaya hudumishwa kwa muda mrefu kuliko ulinzi kutoka kwa maambukizi ya Symptomatic. ikilinganishwa na chanjo zenye msingi wa virusi vya index, Dozi za nyongeza za chanjo za BA.1- au BA. 4/5- zenye mRNA zenye bivalent zinaweza kuongeza ufanisi wa chanjo dhidi ya ugonjwa wa Symptomatic, huku idadi ndogo ya tafiti zinazotathmini matokeo makali zinaonyesha makadirio sawa ya ufanisi wa chanjo. Chanjo za BA.1 - na BA. 4/5- zenye mRNA zenye bivalent huongeza ukubwa na kutoa upana zaidi wa mwitikio wa kinga dhidi ya vibadala vya SARS-CoV-2 vinapotumiwa kama kipim cha nyongeza, ikilinganishwa na virusi vya index - chanjo za msingi. Chanjo za mRNA zenye BA. 4/5 zenye bivalent zilichochea tita za kingamwili zinazopunguza nguvu zaidi ya kizazi cha hivi majui cha Omicron (BQ.1, XBB.1) ikilinganishwa na chanjo za mRNA zenye BA.1 zenye bivalent, zinapotumiwa kama kipimo cha nyongeza.","Ìjábọ̀ ti ìpàdé Ẹgbẹ́ Olùbánidámọ́ràn Iṣẹ́ lórí Èròjà Àjẹsára COVID-19 (TAG-CO-VAC) tó wáyé ní 16-17 oṣù Èrenà ọdún 2023 Ní oṣù Òkudù ọdún 2022, TAG-CO-VAC ṣe àgbéjáde àlàyé fìdíhẹẹ́ tó ń ṣàfihàn pé àwọn àjẹsára adálórí àyẹ̀wo kòkòrò ààrùn ń tẹ̀síwájú láti pèsè àwọn ìpele ààbò tó pọ̀ tako ààrùn tó lágbára tí gbogbo àwọn Ẹ̀ya tó jẹ́ Ẹ̀dun Ọkàn SARS-CoV-2 (VOCs) ń fà, tó fi mọ́ Omicron. Síbẹ̀síbẹ̀, pẹ̀lú ààyè àjèjì adáralóró àti àwọn àìsí ìdánilójú fún ìtẹ̀síwájú àyípadà àkóràn, TAG-CO-VAC náà mọ̀ wí pé ó ṣe é ṣe wí pé ìṣiṣẹ́ àwọn àjẹsára pẹ̀lú àwọn àyẹ̀wo kòkòrò ààrùn máa dínkù lẹ́yìn àkókò díẹ̀. Torí náà TAG-CO-VAC gba àwọn tó ń pèsè àjẹsára àti àwọn aláṣẹ tó ń rí sí òfin nímọ̀ràn láti gbèrò ìsọdituntun fún àwọn èròjà àjẹsára àjèjì adáralóró pẹ̀lú ṣíṣe àfikún Omicron, gẹ́gẹ́ bíi ẹ̀yà àjèjì adáralóró SARS-CoV-2 tó yàtọ̀ jùlọ di àkókò yìí, fún lílò gẹ́gẹ́ bíi oògùn afúnilágbára. Oríṣiríṣi àwọn olùpèsè àjẹsára ti ṣe àgbékalẹ̀ àwọn àjẹsára COVID-19 pẹ̀lú ìsọdituntun àwọn èròjà àjèjì adáralóró; ní UN nínú èyí la ti rí ọ̀pọ̀lọpọ̀ àwọn àjẹsára adálórí-mRNA olókùn-ìran méjì tó ní àwọn ìran ìdílé Omicron tẹ́lẹ̀, ní àfikún sí àyẹ̀wo kòkòrò ààrùn (i.n.p, àyẹ̀wo kòkòrò ààrùn + BA.1 tàbí BA.4/5), tí wọ́n ti fọwọ́sí fún ìlo pàjáwírì fún àwọn aláṣẹ tó ń rí sí òfin. Ní 16-17 oṣù Èrenà ọdún 2023, TAG-CO-VAC tún jókòó papọ̀ ní Muscat, Oman. Pàtàkì fún ìjókòó náà jẹ́ ìpín-méjì: láti ṣe àtúnyẹ́wò ẹ̀rí lórí iṣẹ́ ìsọdituntun àjẹsára COVID-19 tí ó ṣe àfikún àwọn ìran ìdílé Omicron gẹ́gẹ́ bíi oògùn afúnilágbára; àti láti ṣe àgbékalẹ̀ gbèdéke fún àwọn àbá èròjà àjẹsára COVID-19 ní ọdún 2023. Àwọn ẹ̀rí tí TAG-CO-VAC ṣe àtúnyẹ́wò láti ṣe àyẹ̀wo iṣẹ́ ìsọdituntun àjẹsára COVID-19 tí ó ṣe àfikún àwọn ìran ìdílé Omicron ni: (1) àwọn ìwádìí ẹ̀kọ́ nípa àjàkálẹ̀ ààrùn oníwádìí tí wọ́n gbé jáde fún ìṣirò ìṣiṣẹ́ àjẹsára lápapọ̀ àti èyí tó yẹ fún BA.1- tàbí BA.4/5-tó ní àwọn àjẹsára mRNA olókùn-ìran méjì tí wọ́n ń lò gẹ́gẹ́ bíi oògùn afúnilágbára fún àwọn ààrùn tó ní ìdámò àìsàn tó sì lágbára; (2) àwọn dátà adálórí-ààyè-fún-ìmọ̀-ìjìnlẹ̀ lórí títóbi àti ìbú ìfàsẹ́yìn tó kárí fún àwọn ìdáhùn àjẹsára tako àwọn ẹ̀yà SARS-CoV-2 tẹ́lẹ̀ àti èyí tó ń lọ káàkiri tó wà nínú BA.1- tàbí BA.4/5-tó ní àwọn àjẹsára mRNA, ní àfiwé sí àwọn àjẹsára adálórí àyẹ̀wo kòkòrò ààrùn, tí wọ́n ń lò gẹ́gẹ́ bíi oògùn afúnilágbára; àti (3) àwọn ìwádìí adálórí-ààyè-fún-ìmọ̀-ìjìnlẹ̀ àti àwọn dátà ìwádìí lórí ìdáhùn ọpọlọ àjẹsára láti ṣe ìgbéléwọ̀n ipa àṣetúnṣe ifihàn àjèjì adáralóró lórí àjẹsára àti ààbò látara-oọ̀gùn-àjẹsára. Àwọn àlàyé síwájú sí i lórí àwọn ẹ̀rí tí TAG-CO-VAC ṣe àtúnyẹ́wò rẹ̀ ni a lè rí nínú àfikún òfin tí ó tẹ̀lé e. Pẹ̀lú àtúnyẹ́wò dátà náà tí wọ́n ṣàpèjúwe lókè, TAG-CO-VAC náà fẹnukò pé: Àwọn oògùn afúnilágbára fún àwọn àjẹsára adálórí àyẹ̀wo kòkòrò ààrùn ń tẹ̀síwájú láti pèsè àwọn ìpele ààbò tó pọ̀ tako ààrùn tó lágbára àti ikú tí gbogbo àwọn ẹ̀yà SARS-CoV-2 ń fà, tó fi mọ́ àwọn ìran ìdílé Omicron lọ́wọ́lọ́wọ́. Ààbò kúrò lọ́wọ́ ààrùn alágbára àti àwọn àkóràn tó ní ààmì àìsàn tí àwọn àjẹsára adálórí àyẹ̀wo kòkòrò ààrùn ń fà àti BA.1- tàbí BA.4/5-tó ní àwọn àjẹsára mRNA ń dínkù lẹ́yìn àkókò díẹ̀. Síbẹ̀síbẹ̀, ààbò kúrò lọ́wọ́ ààrùn tó lágbára ni àmójútó púpọ̀ wà fún ju ààbò kúrò lọ́wọ́ àwọn àkóràn tí kò ní ààmì àìsàn. Ní àfiwé sí àwọn àjẹsára adálórí àyẹ̀wo kòkòrò ààrùn, àwọn oògùn afúnilágbára fún BA.1- tàbí BA.4/5-tó ní àwọn àjẹsára mRNA lè ṣe àfikún díẹ̀ sí ìṣiṣẹ́ àjẹsára kojú àwọn ààrùn tó ní ààmì ìdámọ̀ àisàn, nígbà tí ònkà kékeré àwọn ìwádìí tó ń ṣe àyẹ̀wo àbájáde tó lágbára ṣe àfihàn àwọn ìṣirò fún ìṣiṣẹ́ àjẹsára tó fara jọ ọ́. Àpapọ BA.1- tàbí BA.4/5-tó ní àwọn àjẹsára mRNA ṣe àtìlẹ́yìn fún pípọ̀ rẹ̀ ó sì ń gba ìbú tó pọ̀ fún ìdáhùn àjẹsára ìfàsẹ́yìn tó kárí fún àwọn ẹ̀ya SARS-CoV-2 nígbà tí wọ́n bá lò ó gẹ́gẹ́ bíi oògùn afúnilágbára, ní àfiwé sí àwọn àjẹsára adálórí àyẹ̀wo kòkòrò ààrùn. BA.1- tàbí BA.4/5-tó ní àwọn àjẹsára mRNA pèsè àwọn àdínkù ìsọdọ̀lẹ àwọn òṣùwọ̀n àjèjì adáralóró tó pọ̀ tako àwọn ìran ìdílé Omicron láìpé yìí (BQ.1, XBB.1) ní àfiwé sí BA.1-tó ní àwọn àjẹsára mRNA, tí wọ́n bá lò ó gẹ́gẹ́ bíi oògùn afúnilágbára.","Umbiko womhlangano weWHO Technical Advisory Group ekwenziweni komgomo weCOVID-19 (TAG-CO-VAC) obubanjwe ngo-16-17 kuNdasa 2023 NgoNhlangulana 2022, iTAG-CO-VAC yashicilela isitatimende sesikhashana siveza imigomo encike kugciiwane lokuqala yaqhubeka yaqinisekisa amazinga aphezulu okuviikelwa okubhekene nezifo ezibucayi ezidalwa yiSARS-CoV-2 yonke ukwahlukana kokukhathazeka (amsVOC) Okufaka Omicron. Kepha ngokunikwa ububanzi besidalasihlungu nokungaqinisekisi ngokuqhubeka kokuguquka kwegciwane iTAG-CO-VAC ibone ukuthi kujwayelekile ukuthi ukusebenza kwemigomo encike kugciwane lokuqala ingehlisa emva kwesikhathi. I-TAG-CO-VAC ngakho yeluleke abakhiqizi bomgomo nabasemagunyeni abalawulayo ukuthi bacabange ukubuyekezwa kokwakhiwa kwesidalasihlungu somgomo okufaka i-Omicron, njengoba bahlukile ngokwesidalasihlungu SARS-CoV-2 ukwahlukana okwamanje, ekuphathweni komgomo wokwengeza. Abakhiqizi abaningi bomgomo sebedevelophe imigomo yeCOVID-19 ngokwenza isidalasihlungu esibuyekeziwe,lokhu kufaka kuncike ku-mRNA yebivalent embalwa ebitholakala ekuqaleni kweOmicrom ukulandelana kozalo, ukwengeza kugciwane lokuqala (lokhu kusho ukuthi, igciwane lenkomba + BA.1 noma BA.4/5) esigunyaziwe kokuphuthumayo ngabasemagunyeni abalalwulayo. Ngomhlaka-16 -17 kuNdasa 2023, iTAG-CO-VAC yaphinde yahlanganisa kuMuscat, e-Oman. Inhloso yalomhlangano ihlukene kabili: ukubheka ubufakazi bokwenza obubuyekeziwe kwemigomo yeCOVID-19 ehlanganisa ukulandelana kozalo kwe-Omicron njengesengeso somgomo; futhi ukwakha izikhathi zokwakhiwa komgomo weCOVID-19 kuziphakamiso ku-2023. Ubufakazi obubuyekezwe yi-TAG-CO-VAC ukuze buhlole ukusebenza kwemithi yokugomela i-COVID-19 ebuyekeziwe ehlanganise izinhlu zozalo ze-Omicron zifakiwe: (1) izifundo zokutholakele kwe-ephidemoloji eshicilelwe ilinganisa okuyikho ngqo nokuhlobene nokusebenza komgomo kweBA.1 noma iBA.4/5 enemigomo yebivalent mRNA esebenza njengesikalo sokwengeza okubhekene nezimpawu nezifo ezibucayi (2) imininingo encike kulebhu kubukhulu nobubanzi bezimpendulo zokusebenza okubhekene nokudlule kokuzungeza kokwahlukana kweSARS-CoV-2 okwehliswa BA.1 noma iBA.4/5 imigomo ene-mRNA uma uqhathanisa nemigomo encike kugciwane lokuqala esetshenziswa njegesikalo sokwengeza (3) izifundo ezisekelwe elabhorethri kanye nedatha yokuqaphela ezimpendulo zenkumbulo yokuzivikela komzimba ukuze kuhlolwe umthelela wokuchayeka okuphindaphindiwe kwe-antigen ekugomeni nasekuvikelweni okubangelwa umgomo. Imininingwane eyengeziwe kubufakazi obubhekiwe yiTAG-CO-VAC bungatholakala ephepheni elihambisanayo. Ngokubhekiwe kwedatha echaziwe ngasenhla, iTAG-CO-VAC iyaphetha: Isikalo sokwengeza kwemigomo encike kugciwane lokuqala iyaqhubeka iqinisekisa amazinga aphezulu okuvikela okubhekene nobucayi bezifo nokufa okudalwa yikona konke ukuhlukana SARS-CoV-2 okufaka okwesikhashana kwe-Omicron ukulandelana kozalo. Ukuvikelwa kuzifo ezibucayi nezinkomba zokuthelelana kulaliswa ukuqala kwemigomo enike kugciwane neBA.1 noma iBA.4/5 enebivalent yemigomo ye-mRNA eehlayo emva kwesikhathi. Kepha ukuvikelwa kulezifo ezibucayi kuyagcineka ngaphezu kokuvikelwa zempawini zokutheleleka. Uma uqhathanisa nemgomo encike kugciwane lokuqala, izikalo zokwengeza zeBA.1 noma iBA4.5 imigomo enebivalent mRNA kunganyusa ukusebenza komgomo okubhekene nezimpawu zezifo ngesikhathi izifundo zenamba encane zihlola imiphumela ebucayi kukhombisa ukufana kwesilinganiso sokusebenza komgomo. Kokubili iBA.1 neBA4/5 yemigomo equkethe mRNA yebivalent yandisa ubukhulu nobukhulu obubanzi bezimpendulo zokusebenza yonke indawo kukwahlukana kweSATS-CoV-2 Ngesikhathi kusetshenziswe njengesikalo sokwengeza uma uqhathanisa nemigomo encike kugciwane lokuqala. BA4/5 imigomo equkethe imRNA yebivalent ilalisa ukulinganisa okukhulu kuzivimbasihlungu okubhekene nokulandelana kozalo kwamanje kweOmicron (BQ.1, XBB.1) uma uqhathanisa nemigomo yeBA.1- equkethe ibivalent yemRNA uma isetshenziswe njengesikalo sokwengeza."
-,,,,,
+የዓለም ጤና ድርጅት ሙያዊ አማካሪ ቡድን በኮቪድ-19 የክትባት ቅንብር (TAG-CO-VAC) እ.ኤ.አ በመጋቢት 16-17 2023 የተካሄደው ስብሰባ ዘገባ። እ.ኤ.አ. በሰኔ 2022 በኮቪድ 19 ክትባት ላይ የሚሰራው አማካሪ ቡድን ጊዜያዊ መግለጫ ሰጥቷል፤ በዋናው ቫይረስ ላይ የተመሰረቱ ክትባቶች አሁንም ኦሚክሮንን (የኮቪድ 19 ዝርያ) ጨምሮ በሁሉም የኮሮና ቫይረስ አይነቶች ከሚመጡ ከባድ በሽታዎች ከፍተኛ የመከላከል አቅም እንደሚሰጡ አሳይቷል። ነገር ግን፣ ከተጨማሪ የቫይረሱ ዝግመተ ለውጥ አንቲጂኒክ ርቀት እና እርግጠኛ አለመሆን አንፃር፣ TAG-CO-VAC በመረጃ ጠቋሚ ቫይረስ ላይ የተመሰረቱ ክትባቶች ከጊዜ ወደ ጊዜ እየቀነሰ እንደሚሄድ ተገንዝቧል። በኮቪድ 19 ክትባት ላይ የሚሰራው አማካሪ ቡድን የክትባት አምራቾች እና የቁጥጥር ባለስልጣናት ኦሚክሮንን ( Omicron) በግምት ውስጥ በማስገባት የክትባት ቀመሩን ስብጥር ማሻሻያ እንዲያደርጉ መክሯል፤ ይህም እስከ አሁን ድረስ ካሉ የኮሮና ቫይረስ አይነቶች በጣም ልዩ የሆነዎን ኦሚክሮንን እንደ ማበልጸጊያ በመጠቀም ነው። በርካታ የክትባት ሰሪዎች የኮቪድ-19 ክትባቶችን ከተሻሻለ ቀመር ፈጥረዋል፤ ይህ የመጀመሪያውን ቫይረስ እና ቀደምት የኦሚክሮን አይነቶችን (እንደ ኢንዴክስ ቫይረስ + BA.1 ወይም BA.4/5) ሁለቱንም የያዙ mRNA ክትባቶችን ያካትታል፤ እነዚህ ክትባቶች በ��ቆጣጣሪ አካላት ለድንገተኛ ጊዜ ጥቅም ላይ እንዲውሉ ተፈቅዷል። እ.ኤ.አ በ16-17 2023፣ TAG-CO-VAC በሙስካት፣ ኦማን ውስጥ እንደገና ተሰበሰበ። የስብሰባው ዓላማ ሁለት ነበር፡. የኦሚክሮን የዘር ሀረጎችን እንደ ተጨማሪ መጠን የሚያካትቱ የዘመኑ የኮቪድ-19 ክትባቶች አፈጻጸም ላይ ያለውን ማስረጃ ለመገምገም፣ እና እ.ኤ.አ. በ2023 የኮቪድ 19 ክትባት ስብጥር መመሪያዎችን የሚወጡበትን ጊዜ ለመወሰን። የኦሚክሮን( Omicron) የዘር ሀረጎችን ያካተቱ የተሻሻሉ የኮቪድ-19 ክትባቶችን አፈጻጸም ለመገምገም በTAG-CO-VAC የተገመገመ ማስረጃ፡- (1) BA.1 ወይም BA.4/5 የያዙ ክትባቶች የበሽታውን ምልክቶች እና የተባባሰ የበሽታውን ደረጃ ከማከም አንጻር ምን ያህል ውጤታማ እንደሆኑ የሚገመግሙ የታተሙ ጥናቶች፤ (2) BA.1 ወይም BA.4/5 የያዙ ክትባቶች የመጀመሪያው ቫይረስ ላይ ተመስርተው ከተሰሩ ክትባቶች ጋር ሲነጻጸሩ በተለያዩ የኮሮና ቫይረስ ዝርያዎች ላይ ምን ያህል ውጤታማ እንደሆኑ የሚያሳይ የላብራቶሪ መረጃ፤ (3) የላቦራቶሪ-ተኮር ጥናቶች እና የበሽታ ተከላካይ ማህደረ ትውስታ ምላሾች ላይ ምልከታ ውሂብ በተደጋጋሚ አንቲጂን መጋለጥ በክትባት-መከላከያ እና ጥበቃ ላይ ያለውን ተጽእኖ ለመገምገም. በኮቪድ 19 ክትባት ላይ በሚሰራው አማካሪ ቡድን የተገመገሙ ማስረጃዎች ላይ ተጨማሪ ዝርዝሮችን በአባሪው ውስጥ ይገኛሉ። ከላይ በተገለጸው መረጃ ግምገማ ላይ በመመስረት፣ TAG-CO-VAC የሚከተለውን ይደመድማል፡- በቫይረስ ኢንዴክስ ላይ የተመሰረቱ ክትባቶችን ከፍ ማድረግ በሁሉም SARS-CoV-2 ልዩነቶች ምክንያት ከሚመጣው ከባድ በሽታ እና ሞት የወቅቱ የኦሚክሮን የዘር ሐረግን ጨምሮ ከፍተኛ ጥበቃ መስጠቱን ቀጥሏል። በመረጃ ጠቋሚ ቫይረስ ላይ የተመሰረቱ ክትባቶች እና BA.1- ወይም BA.4/5-የያዙ bivalent mRNA ክትባቶች ከሚያስከትላቸው ከከባድ በሽታ እና ምልክታዊ ኢንፌክሽን መከላከል በጊዜ ሂደት እየቀነሰ ይሄዳል። ነገር ግን ከከባድ በሽታ መከላከል ምልክታዊ ኢንፌክሽን ከመከላከል ይልቅ ረዘም ላለ ጊዜ ይቆያል. በመጀመሪያው የቫይረስ አይነት ላይ ከተመረኮዙ ክትባቶች ጋር ሲነጻጸር BA.1 ወይም BA.4/5 የያዙ ክትባቶች የኮሮና ህመም ምልክት የሚያሳዩ ሰዎች ላይ ያላቸው ውጤታማነት በጥቂቱ የተሻለ ነው፤ ይሁን እንጂ ከበድ ያለ የበሽታው ደረጃ ላይ በደረሱ ሰዎች ላይ የተደረጉት ጥቂት ጥናቶች እንደሚያሳዩት ተመሳሳይ ውጤታማነት አላቸው። ሁለቱም BA.1 እና BA.4/5 የያዙ ማበልፀጊያ ክትባቶች በመጀመሪያው የቫይረሱ አይነት ላይ ተመስርተው ከተሰሩ ክትባቶች ጋር ሲነፃፀሩ በተለያዩ የኮሮና ቫይረስ ዓይነቶች ላይ የተሻለ አቅም እንዳላቸው ያሳያሉ። BA.4/5 የያዙ ክትባቶች የኦሚክሮን (Omicron ) (BQ.1፣ XBB.1) የኮሮና ቫይረስ አይነትን በመከላከል ረገድ BA.1 ከያዙ ክትባቶች ጋር ሲነፃፀሩ የተሻለ አቅም አላቸው ።,"Report of the meeting of the WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) held on 16-17 March 2023 In June 2022, the TAG-CO-VAC published an interim statement highlighting that index virus-based vaccines continued to confer high levels of protection against severe disease caused by all SARS-CoV-2 Variants of Concern (VOCs), including Omicron. However, given the antigenic distance and uncertainties of further viral evolution, the TAG-CO-VAC recognized that it was likely that the effectiveness of vaccines based on the index virus would reduce over time. The TAG-CO-VAC therefore advised vaccine manufacturers and regulatory authorities to consider an update of vaccine antigen composition by including Omicron, as the most antigenically distinct SARS-CoV-2 variant thus far, for administration as a booster dose. Multiple vaccine manufacturers have developed COVID-19 vaccines with an updated antigenic composition; this includes several bivalent mRNA-based vaccines containing earlier Omicron descendent lineages, in addition to the index virus (i.e., index virus + BA.1 or BA.4/5), which have been authorized for emergency use by regulatory authorities. On 16-17 March 2023, the TAG-CO-VAC reconvened in Muscat, Oman. The purpose of the meeting was two-fold: to review the evidence on the performance of updated COVID-19 vaccines that incorporate descendent lineages of Omicron as a booster dose; and to establish timelines for COVID-19 vaccine composition recommendations in 2023. The evidence reviewed by the TAG-CO-VAC to assess the performance of updated COVID-19 vaccines that incorporated descendent lineages of Omicron included: (1) published observational epidemiological studies of estimates of absolute and relative vaccine effectiveness of BA.1- or BA.4/5-containing bivalent mRNA vaccines used as a booster dose against symptomatic and severe disease; (2) laboratory-based data on the magnitude and breadth of cross-reactive immune responses against previous and circulating SARS-CoV-2 variants induced by BA.1- or BA.4/5- containing mRNA vaccines, as compared to index virus-based vaccines, used as a booster dose; and (3) laboratory-based studies and observational data on immune memory responses to evaluate the impact of repeated antigen exposure on vaccine-induced immunity and protection. Further details on the evidence reviewed by the TAG-CO-VAC can be found in the accompanying annex. Based on the review of the data described above, the TAG-CO-VAC concludes: Booster doses of index virus-based vaccines continue to confer high levels of protection against severe disease and death caused by all SARS-CoV-2 variants, including contemporary Omicron descendent lineages. Protection from severe disease and symptomatic infection induced by index virus-based vaccines and BA.1- or BA.4/5-containing bivalent mRNA vaccines declines over time. However, protection from severe disease is maintained longer than protection from symptomatic infection. As compared to index virus-based vaccines, booster doses of BA.1- or BA.4/5-containing bivalent mRNA vaccines may modestly increase vaccine effectiveness against symptomatic disease, while the small number of studies assessing severe outcomes show similar estimates of vaccine effectiveness. Both BA.1- and BA.4/5-containing bivalent mRNA vaccines enhance the magnitude and elicit greater breadth of cross-reactive immune responses to SARS-CoV-2 variants when used as a booster dose, as compared to the index virus-based vaccines. BA.4/5-containing bivalent mRNA vaccines induced higher neutralizing antibody titres against recent descendent lineages of Omicron (BQ.1, XBB.1) as compared to BA.1-containing bivalent mRNA vaccines, when used as a booster dose.","Rahoton taron Ƙungiyar Ba da Shawarwari na Fasaha ta Hukumar WHO kan Tsarin rigakafin cutar COVID-19 (TAG-CO-VAC) wanda aka gudanar a ranakun 16-17 ga watan Maris 2023 A cikin watan Yunin 2022, TAG-CO-VAC ta buga wata sanarwa ta wucin gadi wacce ke nuna cewa allurar rigakafin ƙwayoyin cutar sun ci gaba da ba da babban matakan kariya daga mummunan cutar da duk SARS-CoV-2 Variants of Concern (VOCs) ke haifarwa, gami da Omicron. Duk da haka, idan aka yi la'akari da sinadarin daidaita garkuwar jiki, an gano cewar akwai rashin tabbas akan cewar allurar Rigakafin TAG-CO-VAC zai cigaba da tasiri bayan wani ɗan lokaci. A don haka masu bayar da shawarwari akan TAG-CO-VAC ta shawarci masu ƙera alluran rigakafi da hukumomin da ke kula da su, da a su yi la’akari da sabunta sinadaran da ke tattare da maganin rigakafi ta hanyar haɗawa da sinadarin Omicron, a matsayin sa na sinadari mafi ƙarfi wajen yaƙar duk wasu nau'ukan cutar SARS-CoV-2 a matsayin maganin samar da kuzari. Masu ƙera alluran rigakafi da yawa sun haɓaka rigakafin COVID-19 tare da sabunta abubuwan antigenic; wannan ya haɗa da alluran rigakafin mRNA da yawa waɗanda ke ƙunshe da nau'ukan Omicron na farko, ban da ƙwayar cuta mai ƙididdigewa (watau ƙwayar cuta + BA.1 ko BA.4/5), waɗanda hukumomin gudanarwa suka bayar da izini don amfanin gaggawa dasu. A ranakun 16-17 ga watan Maris ɗin 2023, kwamitin TAG-CO-VAC ya sake zama a Muscat, wato babban birnin ƙasar Oman. Maƙasudin taron ya kasu kashi biyu: Domin sake nazarin shaida kan ayyukan sabbin rigakafin cutar COVID-19 waɗanda suka haɗa nau'ukan sinadarin Omicron a matsayin sinadarin ƙarin kuzari Domin kafa jadawalin lokaci don shawarwarin haɗa magungunan rigakafin COVID-19 a cikin shekarar 2023. Shaidar nazarin da kwamitin TAG-CO-VAC ta sake dubawa don tantance ayyukan sabbin rigakafin cutar COVID-19 waɗanda suka haɗa nau'ukan Omicron sun haɗa da: (1) An wallafa nazarin cututtukan lura da ƙididdiga na cikakkiyar tasirin maganin rigakafi na BA.1- ko BA.4/5 mai ɗauke da bivalent mRNA alluran rigakafin da aka yi amfani da su a matsayin masu ƙara kuzari akan alamun bayyanar cututtuka da cuta mai tsanani; (2) Bayanan da aka samu akan ɗakin gwaje-gwaje kan girma da faɗin martanin rigakafin na gaba da yaɗuwa da cututtuka mabanbanta masu alaƙa da cutar SARS-CoV-2 waɗanda BA.1- ko BA.4/5- na ɗauke da allurar mRNA, idan aka kwatanta da ƙwayar cuta ta index idan aka kwatanta su da maganin rigakafin da ake amfani da su a matsayin masu ƙara kuzari (3) Nazarin ɗakin gwaje-gwaje da bayanan lura da martanin ƙwaƙwalwar ajiyar rigakafi don kimanta tasirin maimaitawar antigen akan rigakafi da kuma irin kariya da take samarwa. Ana iya samun ƙarin cikakkun bayanai kan shaidar da kwamitin TAG-CO-VAC tayi nazari akai a cikin wasu kundi na nan daba. Dangane da bitar bayanan da aka kwatanta daga farko, kwamitin TAG-CO-VAC ya yanke shawarar: Ƙara yawan allurai na tushen ƙwayoyin cuta suna ci gaba da ba da manyan matakan kariya daga mummunan cutar da rasa rayuka waɗanda duk cututtuka mabanbanta na nau'ukan cutar SARS-CoV-2 suka haifar, gami da nau'ukan sinadarin Omicron na tsawon lokaci. Kariya daga cututtuka masu tsanani da kamuwa da cutar ke haifarwa ta hanyar alluran rigakafin ƙwayoyin cuta da BA.1- ko BA.4/5 mai ɗauke da bivalent mRNA na raguwa akan lokaci. Duk da haka, ana samun kariya daga cututtuka mai tsanani fiye da kariyar da ake samu daga cututtuka masu saurin yaɗuwa. Idan aka kwatanta da alluran rigakafi na tushen ƙwayoyin cuta, masu haɓaka allurai na BA.1- ko BA.4/5-mai ɗauke da bivalent mRNA alluran rigakafi na iya haɓaka tasirin alluran rigakafi a kan bayyanar cututtuka, yayin da ƙaramin adadin binciken da ke tantance sakamako mai tsanani yana nuna ƙididdiga iri ɗaya na rigakafin. Sinadaran BA.1- da BA.4/5-masu ɗauke da bivalent mRNA na alluran rigakafin suna haifar da mafi girman martanin rigakafi ga cututtuka mabambanta nau'ukan SARS-CoV-2 a lokacin da aka yi amfani da su wajen ƙarin kuzari, idan aka kwatanta da ƙwayar cutar tushen alluran rigakafi. BA.4/5 mai ƙunshe da alluran rigakafin mRNA na bivalent sun haifar da mafi girma daidaiton titres antibody a kan kwanan nan na nau'ukan Omicron (BQ.1, XBB.1) idan aka kwatanta da BA.1-ɗauke da bivalent mRNA alluran rigakafi, lokacin da aka yi amfani da matsayin mai ƙara kuzari.","Ripoti ya mkutano wa kikundi cha ushauri wa kiufundi cha WHO kuhusu muundo wa chanjo ya UVIKO-19 (TAG-CO-VAC) uliofanyika tarehe 16-17 Machi 2023. Mnamo Juni 2022, TAG-CO-VAC ilichapisha taarifa ya muda inayoangazia kwamba Chanjo zinazotegemea virusi ziliendelea kutoa viwango vya juu vya ulinzi dhidi ya ugonjwa mbaya unaosababishwa na aina zote za kujali za SARS-CoV-2 (VOCs), pamoja na Omicron. Hata hivyo, kwa kuzingatia umbali wa Antijeni na kutokuwa na uhakika wa mageuzi zaidi ya Virusi, TAG-CO-VAC ilitambua kuwa kuna uwezekano kwamba ufanisi wa chanjo kulingana na virusi vya index ungepungua kwa muda. Hivyo TAG-CO-VAC iliwashauri watengenezaji chanjo na mamlaka za udhibiti kuzingatia sasisho la muundo wa chanjo ya Antijeni kwa kujumuisha Omicron, kama kibadala tofauti kabisa cha SARS-CoV-2 kufikia sasa, kwa matumizi kama Dozi ya nyongeza. Watengenezaji wengi wa chanjo wametengeneza chanjo za UVIKO-19 zilizo na muundo mpya wa Antijeni; hii hujumuisha chanjo kadhaa zenye msingi wa mRNA zenye nasaba za awali za kizazi cha Omicron, pamoja na virusi vya index (yaani; virusi vya index + BA.1 au BA. 4/5, ambazo zimeidhinishwa kwa matumizi ya dharura na mamlaka ya udhibiti. Tarehe 16-17 Machi 2023, TAG-CO-VAC ilikutana tena huko Maskati, Omani. Madhumuni ya mkutano yalikuwa mawili: Kukagua ushahidi kuhusu utendaji kazi wa chanjo zilizosasishwa za UVIKO-19 ambazo zinajumuisha ukoo wa Omicron kama Dozi ya nyongeza; na Ili kuweka ratiba za mapendekezo ya muundo wa chanjo ya UVIKO-19 mwaka 2023. Ushahidi ulikaguliwa na TAG-CO-VAC ili kutathmini utendaji kazi kwa chanjo zilizosasishwa za UVIKO-19 ambazo zilijumuisha ukoo wa Omikroni pamoja na; (1)ilichapisha uchunguzi wa uchunguzi wa magonjwa ya makadirio ya ufanisi kamili na jamaa wa chanjo za BA.1 - au BA. 4/5 - zenye mRNA yenye bivalent zinazotumiwa kama kipimo cha nyongeza dhidi ya ugonjwa wa Symptomatic na kali; (2) Data inayotokana maabara juu ya ukubwa na upana wa mwitikio wa kinga dhidi ya vibadala vya awali na vinavyozunguka vya SARS-CoV-2 vilivyochochewa na chanjo za BA.1- au BA. 4/5- zenye mRNA, ikilinganishwa na chanjo zenye w virusi, kutumika kama kipimo cha nyongeza; na (3) Tafiti zinazotegemea maabara na Data ya uchunguzi kuhusu majibu ya kumbukumbu ya kinga ili kutathmini athari ya kukabiliwa na Antijeni mara kwa mara kwenye kinga na ulinzi unaotokana na chanjo. Maelezo zaidi juu ya ushahidi uliopitiwa na TAG-CO-VAC yanaweza kupatikana katika kiambatisho kinachoambatana. Kulingana na ukaguzi wa Data iliyoelezewa hapo juu, TAG-CO-VAC inahitimisha: Dozi ya nyongeza na chanjo zenye msingi wa virusi vya index zinaendelea kutoa viwango vya juu vya ulinzi dhidi ya ugonjwa mbaya na kifo kinachosababishwa na anuwai zote za SARS-CoV-2, ikijumuisha nasaba za kizazi za kisasa za Omicron. Ulinzi dhidi ya ugonjwa mkali na maambukizi ya Symptomatic yanayotokana na chanjo za virusi vya index na BA.1- au BA. 4/5- zenye bivalent mRNA chanjo hupungua baada ya muda. Hata hivyo, ulinzi kutoka kwa ugonjwa mbaya hudumishwa kwa muda mrefu kuliko ulinzi kutoka kwa maambukizi ya Symptomatic. ikilinganishwa na chanjo zenye msingi wa virusi vya index, Dozi za nyongeza za chanjo za BA.1- au BA. 4/5- zenye mRNA zenye bivalent zinaweza kuongeza ufanisi wa chanjo dhidi ya ugonjwa wa Symptomatic, huku idadi ndogo ya tafiti zinazotathmini matokeo makali zinaonyesha makadirio sawa ya ufanisi wa chanjo. Chanjo za BA.1 - na BA. 4/5- zenye mRNA zenye bivalent huongeza ukubwa na kutoa upana zaidi wa mwitikio wa kinga dhidi ya vibadala vya SARS-CoV-2 vinapotumiwa kama kipim cha nyongeza, ikilinganishwa na virusi vya index - chanjo za msingi. Chanjo za mRNA zenye BA. 4/5 zenye bivalent zilichochea tita za kingamwili zinazopunguza nguvu zaidi ya kizazi cha hivi majui cha Omicron (BQ.1, XBB.1) ikilinganishwa na chanjo za mRNA zenye BA.1 zenye bivalent, zinapotumiwa kama kipimo cha nyongeza.","Ìjábọ̀ ti ìpàdé Ẹgbẹ́ Olùbánidámọ́ràn Iṣẹ́ lórí Èròjà Àjẹsára COVID-19 (TAG-CO-VAC) tó wáyé ní 16-17 oṣù Èrenà ọdún 2023 Ní oṣù Òkudù ọdún 2022, TAG-CO-VAC ṣe àgbéjáde àlàyé fìdíhẹẹ́ tó ń ṣàfihàn pé àwọn àjẹsára adálórí àyẹ̀wo kòkòrò ààrùn ń tẹ̀síwájú láti pèsè àwọn ìpele ààbò tó pọ̀ tako ààrùn tó lágbára tí gbogbo àwọn Ẹ̀ya tó jẹ́ Ẹ̀dun Ọkàn SARS-CoV-2 (VOCs) ń fà, tó fi mọ́ Omicron. Síbẹ̀síbẹ̀, pẹ̀lú ààyè àjèjì adáralóró àti àwọn àìsí ìdánilójú fún ìtẹ̀síwájú àyípadà àkóràn, TAG-CO-VAC náà mọ̀ wí pé ó ṣe é ṣe wí pé ìṣiṣẹ́ àwọn àjẹsára pẹ̀lú àwọn àyẹ̀wo kòkòrò ààrùn máa dínkù lẹ́yìn àkókò díẹ̀. Torí náà TAG-CO-VAC gba àwọn tó ń pèsè àjẹsára àti àwọn aláṣẹ tó ń rí sí òfin nímọ̀ràn láti gbèrò ìsọdituntun fún àwọn èròjà àjẹsára àjèjì adáralóró pẹ̀lú ṣíṣe àfikún Omicron, gẹ́gẹ́ bíi ẹ̀yà àjèjì adáralóró SARS-CoV-2 tó yàtọ̀ jùlọ di àkókò yìí, fún lílò gẹ́gẹ́ bíi oògùn afúnilágbára. Oríṣiríṣi àwọn olùpèsè àjẹsára ti ṣe àgbékalẹ̀ àwọn àjẹsára COVID-19 pẹ̀lú ìsọdituntun àwọn èròjà àjèjì adáralóró; ní UN nínú èyí la ti rí ọ̀pọ̀lọpọ̀ àwọn àjẹsára adálórí-mRNA olókùn-ìran méjì tó ní àwọn ìran ìdílé Omicron tẹ́lẹ̀, ní àfikún sí àyẹ̀wo kòkòrò ààrùn (i.n.p, àyẹ̀wo kòkòrò ààrùn + BA.1 tàbí BA.4/5), tí wọ́n ti fọwọ́sí fún ìlo pàjáwírì fún àwọn aláṣẹ tó ń rí sí òfin. Ní 16-17 oṣù Èrenà ọdún 2023, TAG-CO-VAC tún jókòó papọ̀ ní Muscat, Oman. Pàtàkì fún ìjókòó náà jẹ́ ìpín-méjì: láti ṣe àtúnyẹ́wò ẹ̀rí lórí iṣẹ́ ìsọdituntun àjẹsára COVID-19 tí ó ṣe àfikún àwọn ìran ìdílé Omicron gẹ́gẹ́ bíi oògùn afúnilágbára; àti láti ṣe àgbékalẹ̀ gbèdéke fún àwọn àbá èròjà àjẹsára COVID-19 ní ọdún 2023. Àwọn ẹ̀rí tí TAG-CO-VAC ṣe àtúnyẹ́wò láti ṣe àyẹ̀wo iṣẹ́ ìsọdituntun àjẹsára COVID-19 tí ó ṣe àfikún àwọn ìran ìdílé Omicron ni: (1) àwọn ìwádìí ẹ̀kọ́ nípa àjàkálẹ̀ ààrùn oníwádìí tí wọ́n gbé jáde fún ìṣirò ìṣiṣẹ́ àjẹsára lápapọ̀ àti èyí tó yẹ fún BA.1- tàbí BA.4/5-tó ní àwọn àjẹsára mRNA olókùn-ìran méjì tí wọ́n ń lò gẹ́gẹ́ bíi oògùn afúnilágbára fún àwọn ààrùn tó ní ìdámò àìsàn tó sì lágbára; (2) àwọn dátà adálórí-ààyè-fún-ìmọ̀-ìjìnlẹ̀ lórí títóbi àti ìbú ìfàsẹ́yìn tó kárí fún àwọn ìdáhùn àjẹsára tako àwọn ẹ̀yà SARS-CoV-2 tẹ́lẹ̀ àti èyí tó ń lọ káàkiri tó wà nínú BA.1- tàbí BA.4/5-tó ní àwọn àjẹsára mRNA, ní àfiwé sí àwọn àjẹsára adálórí àyẹ̀wo kòkòrò ààrùn, tí wọ́n ń lò gẹ́gẹ́ bíi oògùn afúnilágbára; àti (3) àwọn ìwádìí adálórí-ààyè-fún-ìmọ̀-ìjìnlẹ̀ àti àwọn dátà ìwádìí lórí ìdáhùn ọpọlọ àjẹsára láti ṣe ìgbéléwọ̀n ipa àṣetúnṣe ifihàn àjèjì adáralóró lórí àjẹsára àti ààbò látara-oọ̀gùn-àjẹsára. Àwọn àlàyé síwájú sí i lórí àwọn ẹ̀rí tí TAG-CO-VAC ṣe àtúnyẹ́wò rẹ̀ ni a lè rí nínú àfikún òfin tí ó tẹ̀lé e. Pẹ̀lú àtúnyẹ́wò dátà náà tí wọ́n ṣàpèjúwe lókè, TAG-CO-VAC náà fẹnukò pé: Àwọn oògùn afúnilágbára fún àwọn àjẹsára adálórí àyẹ̀wo kòkòrò ààrùn ń tẹ̀síwájú láti pèsè àwọn ìpele ààbò tó pọ̀ tako ààrùn tó lágbára àti ikú tí gbogbo àwọn ẹ̀yà SARS-CoV-2 ń fà, tó fi mọ́ àwọn ìran ìdílé Omicron lọ́wọ́lọ́wọ́. Ààbò kúrò lọ́wọ́ ààrùn alágbára àti àwọn àkóràn tó ní ààmì àìsàn tí àwọn àjẹsára adálórí àyẹ̀wo kòkòrò ààrùn ń fà àti BA.1- tàbí BA.4/5-tó ní àwọn àjẹsára mRNA ń dínkù lẹ́yìn àkókò díẹ̀. Síbẹ̀síbẹ̀, ààbò kúrò lọ́wọ́ ààrùn tó lágbára ni àmójútó púpọ̀ wà fún ju ààbò kúrò lọ́wọ́ àwọn àkóràn tí kò ní ààmì àìsàn. Ní àfiwé sí àwọn àjẹsára adálórí àyẹ̀wo kòkòrò ààrùn, àwọn oògùn afúnilágbára fún BA.1- tàbí BA.4/5-tó ní àwọn àjẹsára mRNA lè ṣe àfikún díẹ̀ sí ìṣiṣẹ́ àjẹsára kojú àwọn ààrùn tó ní ààmì ìdámọ̀ àisàn, nígbà tí ònkà kékeré àwọn ìwádìí tó ń ṣe àyẹ̀wo àbájáde tó lágbára ṣe àfihàn àwọn ìṣirò fún ìṣiṣẹ́ àjẹsára tó fara jọ ọ́. Àpapọ BA.1- tàbí BA.4/5-tó ní àwọn àjẹsára mRNA ṣe àtìlẹ́yìn fún pípọ̀ rẹ̀ ó sì ń gba ìbú tó pọ̀ fún ìdáhùn àjẹsára ìfàsẹ́yìn tó kárí fún àwọn ẹ̀ya SARS-CoV-2 nígbà tí wọ́n bá lò ó gẹ́gẹ́ bíi oògùn afúnilágbára, ní àfiwé sí àwọn àjẹsára adálórí àyẹ̀wo kòkòrò ààrùn. BA.1- tàbí BA.4/5-tó ní àwọn àjẹsára mRNA pèsè àwọn àdínkù ìsọdọ̀lẹ àwọn òṣùwọ̀n àjèjì adáralóró tó pọ̀ tako àwọn ìran ìdílé Omicron láìpé yìí (BQ.1, XBB.1) ní àfiwé sí BA.1-tó ní àwọn àjẹsára mRNA, tí wọ́n bá lò ó gẹ́gẹ́ bíi oògùn afúnilágbára.","Umbiko womhlangano weWHO Technical Advisory Group ekwenziweni komgomo weCOVID-19 (TAG-CO-VAC) obubanjwe ngo-16-17 kuNdasa 2023 NgoNhlangulana 2022, iTAG-CO-VAC yashicilela isitatimende sesikhashana siveza imigomo encike kugciiwane lokuqala yaqhubeka yaqinisekisa amazinga aphezulu okuviikelwa okubhekene nezifo ezibucayi ezidalwa yiSARS-CoV-2 yonke ukwahlukana kokukhathazeka (amsVOC) Okufaka Omicron. Kepha ngokunikwa ububanzi besidalasihlungu nokungaqinisekisi ngokuqhubeka kokuguquka kwegciwane iTAG-CO-VAC ibone ukuthi kujwayelekile ukuthi ukusebenza kwemigomo encike kugciwane lokuqala ingehlisa emva kwesikhathi. I-TAG-CO-VAC ngakho yeluleke abakhiqizi bomgomo nabasemagunyeni abalawulayo ukuthi bacabange ukubuyekezwa kokwakhiwa kwesidalasihlungu somgomo okufaka i-Omicron, njengoba bahlukile ngokwesidalasihlungu SARS-CoV-2 ukwahlukana okwamanje, ekuphathweni komgomo wokwengeza. Abakhiqizi abaningi bomgomo sebedevelophe imigomo yeCOVID-19 ngokwenza isidalasihlungu esibuyekeziwe,lokhu kufaka kuncike ku-mRNA yebivalent embalwa ebitholakala ekuqaleni kweOmicrom ukulandelana kozalo, ukwengeza kugciwane lokuqala (lokhu kusho ukuthi, igciwane lenkomba + BA.1 noma BA.4/5) esigunyaziwe kokuphuthumayo ngabasemagunyeni abalalwulayo. Ngomhlaka-16 -17 kuNdasa 2023, iTAG-CO-VAC yaphinde yahlanganisa kuMuscat, e-Oman. Inhloso yalomhlangano ihlukene kabili: ukubheka ubufakazi bokwenza obubuyekeziwe kwemigomo yeCOVID-19 ehlanganisa ukulandelana kozalo kwe-Omicron njengesengeso somgomo; futhi ukwakha izikhathi zokwakhiwa komgomo weCOVID-19 kuziphakamiso ku-2023. Ubufakazi obubuyekezwe yi-TAG-CO-VAC ukuze buhlole ukusebenza kwemithi yokugomela i-COVID-19 ebuyekeziwe ehlanganise izinhlu zozalo ze-Omicron zifakiwe: (1) izifundo zokutholakele kwe-ephidemoloji eshicilelwe ilinganisa okuyikho ngqo nokuhlobene nokusebenza komgomo kweBA.1 noma iBA.4/5 enemigomo yebivalent mRNA esebenza njengesikalo sokwengeza okubhekene nezimpawu nezifo ezibucayi (2) imininingo encike kulebhu kubukhulu nobubanzi bezimpendulo zokusebenza okubhekene nokudlule kokuzungeza kokwahlukana kweSARS-CoV-2 okwehliswa BA.1 noma iBA.4/5 imigomo ene-mRNA uma uqhathanisa nemigomo encike kugciwane lokuqala esetshenziswa njegesikalo sokwengeza (3) izifundo ezisekelwe elabhorethri kanye nedatha yokuqaphela ezimpendulo zenkumbulo yokuzivikela komzimba ukuze kuhlolwe umthelela wokuchayeka okuphindaphindiwe kwe-antigen ekugomeni nasekuvikelweni okubangelwa umgomo. Imininingwane eyengeziwe kubufakazi obubhekiwe yiTAG-CO-VAC bungatholakala ephepheni elihambisanayo. Ngokubhekiwe kwedatha echaziwe ngasenhla, iTAG-CO-VAC iyaphetha: Isikalo sokwengeza kwemigomo encike kugciwane lokuqala iyaqhubeka iqinisekisa amazinga aphezulu okuvikela okubhekene nobucayi bezifo nokufa okudalwa yikona konke ukuhlukana SARS-CoV-2 okufaka okwesikhashana kwe-Omicron ukulandelana kozalo. Ukuvikelwa kuzifo ezibucayi nezinkomba zokuthelelana kulaliswa ukuqala kwemigomo enike kugciwane neBA.1 noma iBA.4/5 enebivalent yemigomo ye-mRNA eehlayo emva kwesikhathi. Kepha ukuvikelwa kulezifo ezibucayi kuyagcineka ngaphezu kokuvikelwa zempawini zokutheleleka. Uma uqhathanisa nemgomo encike kugciwane lokuqala, izikalo zokwengeza zeBA.1 noma iBA4.5 imigomo enebivalent mRNA kunganyusa ukusebenza komgomo okubhekene nezimpawu zezifo ngesikhathi izifundo zenamba encane zihlola imiphumela ebucayi kukhombisa ukufana kwesilinganiso sokusebenza komgomo. Kokubili iBA.1 neBA4/5 yemigomo equkethe mRNA yebivalent yandisa ubukhulu nobukhulu obubanzi bezimpendulo zokusebenza yonke indawo kukwahlukana kweSATS-CoV-2 Ngesikhathi kusetshenziswe njengesikalo sokwengeza uma uqhathanisa nemigomo encike kugciwane lokuqala. BA4/5 imigomo equkethe imRNA yebivalent ilalisa ukulinganisa okukhulu kuzivimbasihlungu okubhekene nokulandelana kozalo kwamanje kweOmicron (BQ.1, XBB.1) uma uqhathanisa nemigomo yeBA.1- equkethe ibivalent yemRNA uma isetshenziswe njengesikalo sokwengeza."
\ No newline at end of file